GoHealthcare MSK Specialty Procedure Library™

Developed by GoHealthcare Practice Solutions

Prior Authorization Process for Neuromodulation

Spinal Cord Stimulation, Dorsal Root Ganglion Stimulation, Peripheral Nerve Stimulation, and Targeted Drug Delivery

An operational, payer-intelligence, and revenue-cycle reference for Pain Management, Orthopedic Surgery, Spine Surgery, Neurosurgery, Neuromodulation Programs, and Ambulatory Surgery Centers.

Explore the Guide Contact GoHealthcare

Important: Educational and operational reference only. Verify all coverage, coding, payer, device, regulatory, and medical-necessity requirements against current primary sources before submission or service delivery.

98%Prior authorization approval rate

FasterTurnaround through specialty-focused workflows

50 StatesNational prior authorization service coverage

ReducedAvoidable denials, appeals, and peer-to-peer reviews

Performance varies by payer, plan, case mix, documentation quality, clinical circumstances, and applicable policy. No approval or payment outcome is guaranteed.

Document Profile

Publication and Use Information

This profile reproduces the approved document attributes and policy-currency notice.

Document Attribute	Detail
Document Title	Prior Authorization Process for Neuromodulation
Library	GoHealthcare MSK Specialty Procedure Library™
Standard Applied	GoHealthcare Clinical Procedure Guide Standard v1.0
Author	Pinky Maniri, Founder and Chief Executive Officer, GoHealthcare Practice Solutions
Publisher	GoHealthcare Practice Solutions — a national Musculoskeletal Specialty Management Services Organization (MSO)
Knowledge Center	https://www.gohealthcarellc.com
Document Type	Cross-cutting process guide (applies across the neuromodulation procedure family)
Version	1.0
Publication Date	July 25, 2026
Policy Currency Sweep	Verified against sources current as of July 2026. Payer policy and Medicare coverage documents change frequently; re-verify before submission.
Intended Audience	Physicians, advanced practice providers, practice administrators, prior authorization specialists, utilization management teams, revenue cycle leaders, clinical documentation specialists, ASC and hospital outpatient leadership, case managers, workers' compensation professionals, attorneys, and healthcare executives.

Guide Navigation

Explore the Complete Neuromodulation Guide

Use the grouped links below to move directly to each section.

Foundation and Evidence

1. Overview
2. Evidence at a Glance
3. Scope of the Neuromodulation Procedure Family
4. Relevant Anatomy (High-Level Overview)
5. Clinical Indications

Selection, Medical Necessity, and Documentation

6. Patient Selection
7. Contraindications
8. Conservative Treatment Requirements
9. Imaging Requirements
10. Medical Necessity
11. Documentation Requirements

Medicare and Commercial Coverage Architecture

12. Medicare Coverage: NCD 160.7 and the Local Coverage Landscape
13. CMS Prior Authorization Program for Certain Hospital Outpatient Department Services
14. The WISeR Model: Technology-Enhanced Prior Authorization in Original Medicare
15. Commercial Payer and Utilization Management Comparison

Authorization Operations and Trial Conversion

16. Prior Authorization Workflow
17. Psychological and Behavioral Health Evaluation
18. Trial-to-Permanent Conversion: Documentation That Determines the Outcome
19. Device Manufacturers and System Considerations

Coding, Denials, Appeals, and Program Intelligence

20. Coding Snapshot
21. Common Prior Authorization Denials
22. Appeal Strategies and Peer-to-Peer Preparation
23. GoHealthcare Clinical Insights
24. GoHealthcare Leadership Perspective
25. GoHealthcare Prior Authorization Insight

Implementation, Case Study, and Future Outlook

26. GoHealthcare Case Study
27. GoHealthcare Best Practices
28. Common Mistakes
29. Pearls and Pitfalls
30. Frequently Asked Questions
31. Key Takeaways
32. Future Outlook

Operational Tools and Publication Controls

36. Recommended Downloads
37. Visual Recommendations

References, Related Reading, and Disclaimer

33. References
34. Reading Recommendations
39. Educational Disclaimer

01

GoHealthcare MSK Specialty Procedure Library™

Overview

Neuromodulation is the most administratively demanding therapy category in musculoskeletal specialty care. No other procedure family combines a mandatory two-stage clinical pathway, a high-cost implantable device, a psychological screening requirement, a federal prior authorization program, a separate federal artificial-intelligence review demonstration, and a commercial payer landscape in which the same therapy may be routinely approved by one utilization management vendor and categorically denied as investigational by another. A practice that treats neuromodulation authorization as a variation on injection authorization will lose cases it should have won.

This guide addresses the operational question that determines whether a neuromodulation program is financially sustainable: how does a practice consistently obtain authorization for trial and permanent implantation while minimizing denials, avoiding unnecessary peer-to-peer reviews, and protecting the facility and the physician from post-payment recovery? It is written for the teams who actually assemble and defend these requests.

The scope is deliberately cross-cutting. Rather than covering a single CPT® code, this guide treats neuromodulation as an authorization pathway spanning spinal cord stimulation (SCS), dorsal root ganglion (DRG) stimulation, peripheral nerve stimulation (PNS), and implantable intrathecal drug delivery systems. These therapies share a common medical necessity architecture — documented refractory pain, exhausted conservative care, multidisciplinary and psychological evaluation, a successful trial, and objective functional measurement — but they diverge sharply in coverage status, and that divergence is where revenue is lost.

Three developments make 2026 a discontinuity rather than an incremental year. First, the Wasteful and Inappropriate Service Reduction (WISeR) Model went live on January 1, 2026, introducing technology-enhanced prior authorization into Original Medicare for electrical nerve stimulator implantation in six states. Second, the long-standing CMS Prior Authorization Program for Certain Hospital Outpatient Department Services continues to govern CPT® 63650 nationwide, and the interaction between the two programs is a common source of avoidable denials. Third, commercial utilization management criteria have moved in opposite directions during the 2026 annual review cycles, with one major vendor relaxing screening requirements while another maintains categorical non-coverage for entire therapy classes. Managing neuromodulation authorization in 2026 requires knowing which rulebook applies to which patient, in which state, at which site of service.

How to Use This Guide

This document is organized to mirror the actual sequence of an authorization: confirm the therapy and the applicable rulebook, establish medical necessity, assemble the documentation packet, route the request correctly, manage the determination, and defend the outcome. Sections 12 through 15 are the coverage-architecture core and should be read together.

• Prior authorization specialists — begin at Section 11 (Documentation Requirements) and Section 16 (Prior Authorization Workflow).
• Physicians and advanced practice providers — Sections 5 through 10 and Section 17 (Psychological Evaluation) address what must appear in the clinical note.
• Revenue cycle and coding teams — Section 20 (Coding Snapshot) and Section 21 (Common Denial Reasons).
• Executives and program directors — Sections 2, 14, 26, and 33.

Back to guide navigation

02

GoHealthcare MSK Specialty Procedure Library™

Evidence at a Glance

The following executive summary consolidates the coverage, evidence, and authorization posture of the neuromodulation family as of July 2026. Each row is expanded in the corresponding section of this guide.

Domain	Summary Position
Medicare National Coverage Determination (NCD)	NCD 160.7, Electrical Nerve Stimulators, is the controlling national policy for implanted spinal cord stimulation. Coverage is conditioned on use as a late resort, failure or unsuitability of other modalities, multidisciplinary screening including psychological evaluation, demonstrated relief during a temporary trial, and adequate facilities and personnel. NCD 160.24 governs deep brain stimulation; NCD 230.18 governs sacral nerve stimulation for urinary incontinence.
Medicare Local Coverage Determination (LCD)	LCD coverage is jurisdiction-dependent and has consolidated. Several MACs retired their SCS LCDs and now apply NCD 160.7 directly, while others maintain active LCDs with additional lead, trial, and lifetime frequency limits. Practices must confirm the LCD status of their own MAC rather than assume a national standard. Peripheral nerve stimulation is separately addressed under LCD L37360 and Article A55531.
Federal Prior Authorization (nationwide)	CPT® 63650 requires prior authorization under the CMS Prior Authorization Program for Certain Hospital Outpatient Department Services. CPT® 63685 and 63688 were temporarily removed from that list and do not currently require OPD prior authorization.
Federal Prior Authorization (WISeR states)	The WISeR Model applies prior authorization or pre-payment review to CPT® 63655 (laminectomy for paddle electrode implantation) under NCD 160.7 in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. CPT® 63650 is expressly excluded from WISeR because it is already covered by the OPD program. Deep brain stimulation implementation is delayed.
Commercial Payer Coverage	Highly variable. SCS is broadly covered for post-laminectomy syndrome and complex regional pain syndrome. DRG stimulation, peripheral nerve stimulation, peripheral nerve field stimulation, and painful diabetic neuropathy are the principal points of divergence, and at least one major utilization management vendor treats several of these as not medically necessary or investigational.
Evidence Level	Randomized controlled trial evidence supports SCS in post-surgical persistent spinal pain and CRPS, and supports 10 kHz SCS in painful diabetic peripheral neuropathy. Evidence for DRG stimulation rests substantially on the ACCURATE trial. Evidence for peripheral nerve field stimulation remains limited. Specialty society guidance is available from ASIPP, ASRA, ASPN, NASS, NANS, and the international neuromodulation community.
Image Guidance Requirements	Fluoroscopic guidance is intrinsic to percutaneous lead placement and is not separately reportable for the neurostimulator implantation codes. Imaging guidance is bundled into several of the integrated-system codes by descriptor.
Prior Authorization Requirements	Effectively universal. Assume prior authorization is required for every trial and every permanent implantation across Medicare Advantage, commercial, Medicaid managed care, workers' compensation, and, in the applicable settings and states, Original Medicare.
Conservative Therapy Requirements	Medicare requires that other modalities have been tried and failed or are unsuitable, without a fixed duration. Commercial vendors typically impose an explicit duration, commonly six consecutive months of physician-supervised conservative management for SCS, and require documentation of physical therapy plus at least one complementary modality.
Trial Requirements	A temporary trial demonstrating relief is a coverage condition under NCD 160.7. The operative threshold applied by most payers and by the CMS OPD program is at least a 50 percent reduction in target pain, or at least a 50 percent reduction in analgesic medication, accompanied by objective functional improvement. WISeR documentation for permanent paddle implantation expects 50 percent pain reduction plus evidence of functional restoration.
Psychological Evaluation	Required by NCD 160.7 as part of multidisciplinary screening. Commercial requirements range from full psychometric testing to a behavioral health attestation, and at least one major vendor removed its behavioral health statement requirement in its June 2026 annual review. Do not assume the requirement has been waived for your plan.
Key Documentation Requirements	Validated pain and function scores at baseline and after each intervention; itemized conservative care with dates and outcomes; imaging correlated to the clinical syndrome; psychological or behavioral health evaluation; trial results with percentage relief and functional change; device and manufacturer identification; and a narrative medical necessity statement written to the specific applicable criteria.
Typical Approval Considerations	Approvals turn on whether the documentation demonstrates that neuromodulation is a late resort for an appropriately screened patient with an objectively measured, refractory, predominantly neuropathic pain syndrome, and whether the trial result is documented in the payer's own language. Denials most often reflect documentation architecture rather than clinical inappropriateness.
Site of Service	Hospital outpatient department, ambulatory surgery center, and office settings are all in scope depending on the code and the program. WISeR applies to Place of Service 11, 12, 19, 22, and 24, and to facility rather than professional claims in the hospital outpatient and ASC settings.

The Single Most Important Operational Fact in This Guide

Neuromodulation is governed by three simultaneous and non-overlapping federal prior authorization regimes plus the commercial layer, and which one applies depends on the CPT® code, the state, and the site of service — not on the therapy.

• CPT® 63650 in a hospital outpatient department: CMS Prior Authorization Program for Certain Hospital OPD Services. Nationwide.
• CPT® 63655 in Arizona, New Jersey, Ohio, Oklahoma, Texas, or Washington: WISeR Model prior authorization or pre-payment review.
• Everything else under Original Medicare: no advance authorization, but full exposure to post-payment review against NCD 160.7 and the applicable LCD.
• Medicare Advantage, commercial, Medicaid managed care, and workers' compensation: the plan's own criteria or its delegated utilization management vendor's criteria.

Back to guide navigation

03

GoHealthcare MSK Specialty Procedure Library™

Scope of the Neuromodulation Procedure Family

Neuromodulation is not a single service. Correctly scoping the request is the first operational decision, because scope determines which coverage document, which vendor criteria set, and which authorization pathway apply. The table below defines the families addressed in this guide.

Therapy Family	Description and Authorization Character
Spinal Cord Stimulation (SCS) / Dorsal Column Stimulation	Epidural placement of percutaneous electrode arrays or a surgical plate/paddle electrode connected to an implanted pulse generator. The highest-volume neuromodulation family and the one most heavily regulated. Two-stage: trial then permanent. Covered under NCD 160.7 and applicable LCDs.
Dorsal Root Ganglion (DRG) Stimulation	Leads placed in the epidural space targeting a specific dorsal root ganglion. The principal U.S. indication is complex regional pain syndrome and causalgia of the lower extremities. Reported with the spinal neurostimulator code family. Coverage is the sharpest point of commercial divergence in the entire category.
Peripheral Nerve Stimulation (PNS)	Percutaneous or open placement of an electrode array on or near a named peripheral nerve, with either a separate pulse generator or an integrated single-component neurostimulator. Includes temporary 60-day systems and permanent systems. Coverage is inconsistent and vendor-dependent.
Peripheral Nerve Field Stimulation (PNfS) / Subcutaneous Field Stimulation	Electrodes placed subcutaneously in the region of maximal pain without a named target nerve. Reported with unlisted code 64999. Widely considered investigational; approvals are rare and should be pursued only with a clear-eyed expectation of denial and appeal.
Implantable Intrathecal Drug Delivery (Targeted Drug Delivery)	A programmable implanted pump and intrathecal catheter delivering analgesic or antispasmodic agents. Two-stage: screening trial then permanent implantation. Governed by separate payer policies and by drug-specific and concentration-specific requirements.
Sacral Nerve Stimulation (SNS)	Included here because it shares codes, vendors, and the WISeR footprint with the pain families, and because MSK programs frequently share operative and authorization infrastructure with urology. Governed by NCD 230.18 for urinary indications.
Cranial and Deep Brain Stimulation	Referenced for completeness. Deep brain stimulation is governed by NCD 160.24 and was expressly delayed from WISeR implementation at model launch, in part because the first-stage electrode implantation codes are on the Medicare Inpatient Only list.

GoHealthcare Clinical Insight: Scope Errors Are Denial Errors

A substantial share of neuromodulation denials that reach appeal are not clinical disagreements. They are scope mismatches introduced at intake. The most common pattern is a request submitted under a spinal cord stimulation policy when the planned procedure is peripheral nerve stimulation, or a field-stimulation procedure submitted under a named-nerve policy. The reviewer applies the criteria in the policy that was invoked, finds them unmet, and issues a denial that is technically correct and clinically irrelevant.

• Confirm the exact planned device and approach with the implanting physician before selecting a policy, not after.
• If the device has no named target nerve, expect unlisted-code handling and build the request accordingly from the outset.
• Never let scheduling staff select the authorization policy from the procedure title alone.

Back to guide navigation

04

GoHealthcare MSK Specialty Procedure Library™

Relevant Anatomy (High-Level Overview)

Anatomy is presented only to the extent required to understand medical necessity, documentation, and coverage criteria. This section is not a procedural or technique reference.

Structures Relevant to Coverage Language

• Epidural space. The potential space external to the dura mater, containing fat and the venous plexus. Percutaneous SCS electrode arrays and DRG leads are positioned here. Coverage language distinguishing percutaneous from open placement turns on how this space is accessed.
• Dorsal columns. The ascending sensory tracts of the posterior spinal cord targeted by conventional SCS. The historical term dorsal column stimulation persists in Medicare and several commercial policy titles, which is why policy searches must include both terms.
• Dorsal root ganglion. A cluster of sensory neuron cell bodies located in the intervertebral foramen. Its discrete, focal somatotopic organization is the clinical rationale for targeting it in focal neuropathic syndromes such as complex regional pain syndrome, and is the basis of the argument that DRG stimulation is not substitutable with conventional dorsal column stimulation.
• Named peripheral nerves. Discrete peripheral nerves, for example the genicular, suprascapular, tibial, or occipital nerves, that can be targeted with an electrode array. The presence or absence of a named target nerve is the coding and coverage dividing line between peripheral nerve stimulation and peripheral nerve field stimulation.
• Intrathecal (subarachnoid) space. The cerebrospinal-fluid-containing space where an intrathecal catheter tip is positioned for targeted drug delivery, permitting analgesia at a fraction of systemic dosing.
• Implant pocket. The subcutaneous pocket created to house a pulse generator, receiver, or pump. Whether a pocket is created and whether a connection between array and generator is required is the structural distinction between the two-component and integrated single-component code families.

Documentation note: coverage reviewers read anatomy through the lens of the code descriptor. An operative plan describing an integrated single-component device will not support a code that requires pocket creation and a detachable connection, and the reverse is equally true. Align the described anatomy, the device, and the code before submission.

Back to guide navigation

05

GoHealthcare MSK Specialty Procedure Library™

Clinical Indications

The indications below reflect the union of Medicare policy, commercial coverage positions, and specialty society guidance. Inclusion in this list does not imply that a given payer covers the indication; Section 15 addresses divergence explicitly.

Indication	Coverage Posture in Practice
Persistent spinal pain syndrome after spinal surgery (post-laminectomy syndrome, historically failed back surgery syndrome) with predominant neuropathic limb pain	The strongest and most consistently covered SCS indication across Medicare and commercial payers. The anchor indication for high-frequency stimulation coverage.
Complex regional pain syndrome (CRPS) Type I and Type II / reflex sympathetic dystrophy	Broadly covered for SCS. Commonly restricted to the extremities and excluded for the head, face, neck, trunk, perineum, pelvis, and abdominal viscera. Payers generally require the diagnosis to be established using the Budapest clinical criteria. This is also the principal indication for DRG stimulation.
Painful diabetic peripheral neuropathy (PDN) refractory to conventional management	The most consequential coverage divergence in neuromodulation. Supported by randomized evidence and FDA-approved indications, accessible under Medicare in jurisdictions applying NCD 160.7 without restrictive LCD diagnosis limits, and added by at least one commercial utilization management vendor under strict criteria — yet expressly listed as not medically necessary in at least one other major vendor's criteria set.
Chronic critical limb ischemia with ischemic rest pain, not revascularizable	Covered by several commercial criteria sets under demanding objective vascular thresholds, typically requiring vascular surgery attestation that reconstruction is not feasible, Rutherford grade II category 4 disease, and specified ankle and toe pressure findings.
Refractory angina pectoris (Canadian Cardiovascular Society class III or IV)	Covered by several commercial criteria sets where optimal medical therapy has failed and the patient is not a revascularization candidate. Low volume in MSK practice but operationally important because approval turns on cardiology attestation.
Chronic intractable pain of the trunk or limbs, predominantly neuropathic, refractory to conventional management	The broad Medicare framing. Under NCD 160.7 the emphasis is on intractability and late resort rather than on a specific named diagnosis, which is why jurisdictions without a restrictive LCD offer broader access than most commercial plans.
Focal peripheral neuropathic pain attributable to a named peripheral nerve	The peripheral nerve stimulation indication. Coverage is inconsistent: some payers cover PNS with criteria analogous to SCS, and at least one major vendor classifies peripheral nerve stimulation as experimental, investigational, or unproven for pain.
Severe chronic pain of malignant or non-malignant origin, or severe spasticity, refractory to systemic therapy	The intrathecal drug delivery indication. Coverage generally requires demonstrated failure of or intolerance to systemic therapy and a successful screening trial, and is further conditioned on the specific agent and concentration.
Post-herpetic neuralgia, phantom limb pain, spinal cord injury dysesthesia, visceral and pelvic pain, chronic axial pain without prior surgery, multiple sclerosis neuropathic pain	Frequently requested and frequently denied. Several major criteria sets list these explicitly as not medically necessary for dorsal column stimulation. Approach these as medical-exception or appeal pathways, and set physician and patient expectations accordingly at intake.

Back to guide navigation

06

GoHealthcare MSK Specialty Procedure Library™

Patient Selection

Patient selection is where clinical judgment and payer criteria converge most tightly. Every element below is simultaneously a clinical predictor of therapeutic success and a documentation element that reviewers search for.

Core Selection Elements

• Pain character and distribution. Neuromodulation is best suited to neuropathic pain. Document the neuropathic character explicitly, with distribution mapped to a dermatomal, peripheral nerve, or regional pattern that corresponds to the intended stimulation target.
• Duration and intractability. Document duration of the current episode and the sequence of therapies attempted. Medicare's framing is that stimulation is a late resort, if not a last resort. Commercial vendors typically convert this

into an explicit minimum duration of supervised conservative management.

• Objective severity and functional impairment. Record a validated pain score and a validated function score at baseline and at each reassessment. Payers increasingly require that the same instrument be repeated so that change is measurable rather than asserted.
• Absence of a correctable structural lesion. Document that surgery is either not indicated, has failed, or has been declined by the patient after shared decision-making. An unaddressed surgically correctable lesion is a reliable denial trigger.
• Multidisciplinary evaluation. NCD 160.7 conditions coverage on careful screening, evaluation, and diagnosis by a multidisciplinary team, and WISeR documentation expectations for permanent paddle implantation name psychological, surgical, medical, and physical therapy evaluation.
• Psychological and behavioral health suitability. Addressed in detail in Section 17. The evaluation must affirmatively address suitability, not merely note that an evaluation occurred.
• Ability to manage the device. Document cognitive capacity, manual dexterity, availability of caregiver support where relevant, and the patient's ability to charge, operate, and report problems with the system.
• Medical optimization. Document glycemic control for diabetic patients, infection screening, anticoagulation planning, and management of comorbidities that raise implant risk.
• Realistic expectation setting. Document the shared decision-making conversation, including the possibility of partial relief, the need for reprogramming, battery and recharging considerations, MRI implications, and the possibility of explant.

Predictors Reviewers Weigh Negatively

• Predominantly axial or nociceptive pain without a neuropathic component.
• Untreated or inadequately controlled depression, anxiety, post-traumatic stress disorder, somatization, or active substance use disorder.
• Active, unresolved secondary-gain context documented without mitigation, including certain litigation and disability determinations.
• Absent, incomplete, or purely narrative conservative care documentation.
• Nonadherence to prior treatment plans documented without explanation or remediation.
• Active local or systemic infection, uncorrected coagulopathy, or an anticipated MRI requirement without a plan.

Back to guide navigation

07

GoHealthcare MSK Specialty Procedure Library™

Contraindications

Contraindications are presented as a documentation obligation. Several payer criteria sets and the WISeR documentation expectations require affirmative documentation that specified contraindications are absent . Silence is read as absence of assessment, not absence of the condition.

Absolute and Near-Absolute

• Active systemic infection, bacteremia, or infection at the planned incision or implant site.
• Uncorrected coagulopathy or an anticoagulation regimen that cannot be safely interrupted.
• Inability to operate the device or to provide informed consent, without adequate caregiver support.
• Failure of the temporary trial to produce the threshold clinical benefit required by the applicable policy.
• Documented allergy or hypersensitivity to a device component or, for intrathecal therapy, to the intended agent.

Relative Contraindications Requiring Documented Mitigation

• Inadequately controlled psychiatric illness, active suicidality, or untreated substance use disorder.
• Anticipated need for MRI that exceeds the MR conditional labeling of the intended system. This is a growing denial and post-implant dissatisfaction driver and is addressed in Section 19.
• Presence of another active implanted device, including cardiac pacemakers, implantable cardioverter-defibrillators, and other neurostimulators, without a documented interaction and interrogation plan.
• Anatomy precluding safe percutaneous access, including prior instrumentation, epidural fibrosis, or severe stenosis at the target level. Note that this same finding, properly documented, is what supports a paddle-electrode approach under WISeR.
• Progressive or unstable neurological deficit requiring surgical evaluation before neuromodulation is considered.
• Immunosuppression, poorly controlled diabetes, or active tobacco use, each of which should be accompanied by documented optimization efforts.
• Pregnancy, or planned pregnancy, given limited safety data.

Back to guide navigation

08

GoHealthcare MSK Specialty Procedure Library™

Conservative Treatment Requirements

Conservative care documentation is the most frequent single point of failure in neuromodulation authorization. The problem is rarely that conservative care did not occur. The problem is that it was delivered over years, by multiple providers, across multiple record systems, and was never assembled into a single itemized, dated, outcome-bearing record that a reviewer can evaluate in one pass.

What Payers Look For

Element	What Satisfies a Reviewer
Pharmacologic therapy	Agent class, specific drug, dose, dates started and stopped, and the reason for discontinuation. Neuropathic agents such as membrane stabilizers and serotonin-norepinephrine reuptake inhibitors carry particular weight for neuropathic indications. Record intolerance and contraindication with the same specificity as failure.
Physical therapy or structured exercise	Provider, dates, number of visits, the specific program, adherence, and the measured outcome. Where formal therapy was not possible, several criteria sets accept a supervised home program with documented initial instruction, patient redemonstration, and confirmed compliance. Document the exception rationale explicitly if therapy was not feasible.
Interventional procedures	Dates, levels, laterality, agents, and percentage and duration of relief for each prior injection, block, or ablation. Several criteria sets require that appropriate interventional modalities have been attempted before neuromodulation.
Psychological and behavioral therapy	Cognitive behavioral therapy, pain coping programs, or a functional restoration program. This is named explicitly in the WISeR documentation expectations for permanent implantation and is frequently the missing element.
Surgical consideration	Documentation that surgery is not indicated, has failed, or was declined after shared decision-making. A surgical consultation note is stronger than a pain physician's assertion.
Duration	Medicare imposes no fixed minimum, framing the requirement as late resort. Commercial vendors commonly require six consecutive months of physician-supervised conservative management for SCS. Build to the longer standard.
Active participation	Evidence that the patient is engaged in an ongoing active rehabilitation program, home exercise program, or functional restoration program at the time of the request, not merely that such a program occurred historically.

GoHealthcare Prior Authorization Insight: The Conservative Care Ledger

The highest-yield operational intervention available to a neuromodulation program is the standing conservative care ledger — a single structured document, maintained in the chart from the first pain visit forward, that accumulates every modality, date, dose, and outcome. Practices that maintain one convert candidates faster, approve at higher rates, and are far better positioned in post-payment review. Practices that reconstruct conservative care at the moment of request routinely discover that the therapy notes are at an outside facility, the medication trial predates the current electronic record, and the only available documentation is the phrase "failed conservative therapy."

• Build the ledger as a discrete note type or flowsheet, not as free text buried in progress notes.
• Capture outcome as a percentage and a duration, never as "no relief" or "some help."
• Request outside records at the first neuromodulation discussion, not at the point of authorization.
• Record contraindications and intolerances with the same rigor as failures. A documented contraindication satisfies most criteria sets as fully as a documented trial.

Back to guide navigation

09

GoHealthcare MSK Specialty Procedure Library™

Imaging Requirements

Imaging serves three distinct functions in a neuromodulation authorization: it corroborates the pain generator, it excludes conditions that would redirect care, and it establishes the technical rationale for the planned approach. Each function requires different documentation.

• Corroboration. Advanced imaging, generally magnetic resonance imaging or computed tomography where MRI is contraindicated, should correspond to the clinical syndrome. Reviewers look for concordance between the imaging finding, the physical examination, and the intended stimulation target. A discordant study is worse than no study.
• Exclusion. Imaging should exclude infection, malignancy, fracture, progressive neurological compression, and other conditions requiring redirection of care.
• Technical rationale. For paddle-electrode requests, imaging documenting prior instrumentation, epidural scarring, challenging anatomy, or a technical barrier to percutaneous placement is a required element of the WISeR documentation expectation. The record must affirmatively state that the patient is not a candidate for percutaneously placed leads and explain why.
• Intraprocedural guidance. Fluoroscopic guidance is integral to percutaneous lead placement and is not separately reportable with the neurostimulator implantation codes. Several integrated-system codes include imaging guidance in the descriptor.
• Currency. Several criteria sets specify recency windows for advanced imaging where the finding is dynamic, such as disc herniation, while permitting older studies where the lesion is fixed. Confirm the applicable window for the specific plan rather than applying a general rule.
• Independent interpretation. At least one major vendor requires that imaging be performed and interpreted by an independent radiologist and provides that the radiology report supersedes conflicting interpretations. Submit the formal report, not the ordering physician's summary of it.
• Vascular imaging. For critical limb ischemia indications, angiographic or cross-sectional vascular imaging demonstrating multilevel disease, together with objective pressure measurements, is required by the criteria sets that cover this indication.
• Future MRI planning. Document the patient's anticipated MRI needs and confirm that the selected system's MR conditional labeling accommodates them. This belongs in the authorization record, not only in the consent discussion.

Back to guide navigation

10

GoHealthcare MSK Specialty Procedure Library™

Medical Necessity

Medical necessity for neuromodulation is a narrative argument built from discrete documentation elements. Reviewers are not evaluating whether the physician believes the therapy is indicated. They are evaluating whether the record independently establishes each criterion in the applicable policy. The distinction is the whole of the discipline.

The Six-Element Medical Necessity Architecture

1. An established, specific diagnosis. Named, coded to the highest available specificity, and supported by history, examination, and corroborating study. Avoid unspecified codes where a specific code exists.
2. Documented refractoriness. An itemized record of failed, contraindicated, or intolerable conservative and interventional therapy, with dates and measured outcomes, meeting the duration standard of the applicable policy.
3. Objective severity and functional impairment. Validated pain and function instruments at baseline, with the impact on activities of daily living described concretely rather than generically.
4. Appropriate screening. Multidisciplinary evaluation including psychological or behavioral health assessment that affirmatively addresses suitability, plus surgical, medical, and physical therapy input as applicable.
5. Demonstrated trial benefit. For permanent implantation, a documented temporary trial producing the threshold benefit — commonly at least 50 percent pain reduction or at least 50 percent analgesic reduction — together with objective functional improvement, measured on the same instruments used at baseline.
6. Reasonable expectation of durable benefit. A stated plan for programming, follow-up, outcome measurement, and, where applicable, opioid reduction.

Writing the Medical Necessity Statement

The medical necessity statement is a short, structured narrative authored or attested to by the treating physician, placed at the front of the submission packet, and written to the criteria of the specific payer being addressed. It should not be a generic letter. An effective statement names the policy, addresses each criterion in the policy's own sequence, cites the specific chart location supporting each criterion, and closes with the requested codes, laterality, levels, device, and site of service.

Medical Necessity Statement — Structural Template

• Line 1. Patient, date, requested procedure, CPT® codes, site of service, and the specific policy or coverage document being addressed by name and identifier.
• Paragraph 1. Diagnosis, duration, character, distribution, and the corroborating imaging or diagnostic finding.
• Paragraph 2. Itemized conservative and interventional care with dates and measured outcomes. Reference the conservative care ledger.
• Paragraph 3. Baseline pain and function scores on named instruments, and the concrete functional deficit.
• Paragraph 4. Multidisciplinary and psychological evaluation findings and the explicit suitability conclusion.
• Paragraph 5. For permanent requests: trial dates, percentage pain reduction, analgesic change, and functional change on the same instruments.
• Paragraph 6. Why this therapy, this device, and this approach; why alternatives were rejected; and, for paddle requests, why percutaneous placement is not appropriate.
• Closing. Affirmative statement that the listed contraindications were assessed and are absent, plus the follow-up and outcome measurement plan.

Back to guide navigation

11

GoHealthcare MSK Specialty Procedure Library™

Documentation Requirements

The checklists below are working instruments. They are organized by request type because the trial packet and the permanent implantation packet are different documents with different failure modes.

Checklist A — Trial / Temporary Electrode Placement

• Specific diagnosis, coded to highest specificity, with duration of the current episode
• Neuropathic character and distribution documented and mapped to the intended target
• Validated pain score at baseline on a named instrument (for example NRS or VAS)
• Validated function or disability score at baseline on a named instrument
• Concrete description of functional impairment in activities of daily living
• Itemized pharmacologic history: agent, dose, dates, outcome, reason for discontinuation
• Itemized physical therapy or supervised home program: provider, dates, visits, adherence, outcome (or documented exception rationale)
• Itemized prior interventional procedures: dates, levels, laterality, percent relief, duration
• Psychological or behavioral therapy history (cognitive behavioral therapy, functional restoration, pain coping program)
• Surgical status: not indicated, failed, or declined after shared decision-making
• Advanced imaging report (formal radiology interpretation) correlated to the clinical syndrome
• Psychological or behavioral health evaluation with an explicit suitability conclusion
• Multidisciplinary evaluation documentation (psychological, surgical, medical, physical therapy)
• Affirmative statement that listed contraindications were assessed and are absent
• Device manufacturer, system, and model identified, with MR conditional status addressed
• Anticipated MRI needs documented and reconciled with device labeling
• Informed consent and shared decision-making note, including realistic expectation setting
• Requested CPT® codes, laterality, levels, units, and planned site of service
• Physician-signed medical necessity statement written to the named applicable policy
• Confirmation of which authorization program applies (OPD program, WISeR, or plan criteria)

Checklist B — Permanent Implantation (Adds to Checklist A)

• Trial dates: date of temporary electrode placement and date of removal
• Percentage reduction in target pain during the trial, on the same instrument used at baseline
• Percentage reduction in analgesic medication during the trial, with specific agents and doses
• Objective functional improvement during the trial on the same instrument used at baseline
• Patient-reported functional gains described concretely (specific activities regained)
• Explicit statement that the trial met the threshold in the applicable policy
• Absence of trial complications, or complications documented with resolution
• Confirmation that the implanting physician performed the trial, or written notification to the patient identifying the referral surgeon where the implanter differs
• For paddle/laminectomy requests: documented technical rationale that the patient is not a candidate for percutaneously placed leads (prior instrumentation, challenging anatomy, elevated body mass index, or other technical barrier)
• Device model, manufacturer, waveform capability, and rechargeable status confirmed
• Programming and follow-up plan, including outcome measurement intervals
• For hospital OPD claims: Unique Tracking Number from the trial authorization, where applicable

Checklist C — Revision, Replacement, and Removal

• Original implantation date, device model, and manufacturer
• Nature of the failure: end of service, battery depletion, malfunction, migration, fracture, erosion, or infection
• Documentation that the device cannot be repaired and is no longer under warranty, where the policy requires it
• Documented therapeutic benefit from the existing system prior to the failure
• Interrogation or diagnostic findings supporting the failure determination
• For replacement with a different modality or manufacturer: explicit clinical rationale, because several criteria sets treat modality substitution as not medically necessary
• Confirmation of whether a new trial is required by the applicable policy (several LCDs provide that a new trial is not required for replacement of a well-functioning system at end of service)

Documentation Anti-Patterns That Reliably Produce Denials

• "Failed conservative therapy" with no itemization, dates, or outcomes.
• "Patient reports significant relief with the trial" without a percentage.
• "Psych cleared" without a report, a date, or a stated suitability conclusion.
• Baseline measured on one instrument and follow-up measured on another, making change unquantifiable.
• Imaging referenced in the note but not submitted, or submitted as a physician summary rather than the formal radiology report.
• A generic medical necessity letter reused across payers that never names the policy it is addressing.
• A paddle-electrode request with no statement of why percutaneous placement is inappropriate.
• Copy-forward documentation in which the baseline pain score is identical across a year of visits, which undermines the credibility of the entire record.

Back to guide navigation

12

GoHealthcare MSK Specialty Procedure Library™

Medicare Coverage: NCD 160.7 and the Local Coverage Landscape

National Coverage Determination 160.7, Electrical Nerve Stimulators

NCD 160.7 is the controlling national policy for implanted spinal cord stimulation and has been in place, in substance, for decades. Its structure is deceptively simple, and its conditions are the origin of nearly every commercial criterion that follows. Summarized, coverage of implanted stimulation for chronic intractable pain is conditioned on the following.

• Stimulation is used only as a late resort, if not a last resort, for patients with chronic intractable pain.
• Other treatment modalities — pharmacologic, surgical, physical, or psychological — have been tried and did not prove satisfactory, or are judged unsuitable or contraindicated for the given patient.
• The patient has undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to implantation, and that screening includes psychological as well as physical evaluation.
• All facilities, equipment, and professional and support personnel required for proper diagnosis, treatment, training, and follow-up are available.
• Demonstration of pain relief with a temporarily implanted electrode precedes permanent implantation.

Operational consequence: NCD 160.7 does not enumerate covered diagnoses. In jurisdictions where no restrictive LCD is in effect, this creates materially broader access than most commercial policies permit — including for indications such as painful diabetic peripheral neuropathy. The corollary is that the entire coverage burden falls on the documentation of intractability, screening, and trial response, and that post-payment review is the enforcement mechanism.

Related National Coverage Determinations

NCD	Subject	Relevance
160.7	Electrical Nerve Stimulators	Controlling policy for implanted spinal cord stimulation. The WISeR Model's electrical nerve stimulator category is built on this NCD.
160.1	Induced Lesions of Nerve Tracts	Neurolytic destruction procedures. Included in the WISeR Model with an initial focus on trigeminal nerve neurolysis.
160.18	Vagus Nerve Stimulation	Refractory partial onset seizures, and treatment-resistant depression under Coverage with Evidence Development. Included in WISeR for initial implantation.
160.19	Phrenic Nerve Stimulator	Ventilatory insufficiency and central sleep apnea indications. Included in WISeR.
160.24	Deep Brain Stimulation	Movement disorder indications. Implementation in WISeR was expressly delayed at model launch, in part because the first-stage electrode implantation codes are on the Medicare Inpatient Only list.
230.18	Sacral Nerve Stimulation for Urinary Incontinence	Urge incontinence, urgency-frequency syndrome, and urinary retention. Included in WISeR for permanent implantation only.

The Local Coverage Determination Landscape

The LCD landscape for spinal cord stimulation has consolidated meaningfully and is now genuinely non-uniform across the country. Several Medicare Administrative Contractors retired their spinal cord stimulation LCDs and now apply NCD 160.7 directly, while others maintain active LCDs that impose additional constraints not present in the NCD. This is not a technicality. It determines whether a diagnosis-to-procedure edit will automatically deny the claim, and it determines the frequency limits that apply.

Constraints that appear in active SCS LCDs and their associated billing and coding articles, and that do not appear in NCD 160.7, include the following. Each must be verified against the current version of the specific document that governs the practice's jurisdiction.

• Lifetime and per-region limits on the number of temporary trials, expressed per anatomic spinal region per patient per lifetime, with limited exceptions for technical failure or a different stimulation modality.
• Limits on the number of permanent plate/paddle implantations per patient per lifetime.
• Limits on the number of leads or contacts reimbursed per implantation.
• A statement that a repeat trial after a failed trial is not appropriate absent documented extenuating circumstances, with additional documentation permitted on appeal.
• Frequency limits on electronic analysis and programming services, commonly expressed as not more often than once every 30 days.
• Diagnosis-to-procedure code edits that drive automated denials, published in the associated billing and coding article rather than in the LCD itself.
• A provision that a new trial is not required to replace a well-functioning stimulator at end of service, for battery change, or for malfunction.
• Guidance that it is preferable for the physician performing the trial to perform the permanent implantation, and that where this is not possible the patient should be informed in writing and given the name of the referring surgeon.

GoHealthcare Prior Authorization Insight: Verify Your Own MAC, Every Quarter

Because ICD-10-CM and CPT® code lists have migrated out of LCDs and into separate billing and coding articles, and because several SCS LCDs have been retired while others remain active, the only reliable method is to check the Medicare Coverage Database for the practice's own state on a fixed cadence. A retired LCD still returns search results and archived versions, which is precisely how stale criteria end up embedded in an authorization template and quietly generate denials for a year.

• Search by state, not by document number, at https://www.cms.gov/medicare-coverage-database
• Check both the LCD and its associated billing and coding article. The article holds the diagnosis edits.
• Record the document identifier, version, and revision date in the authorization template so the source of any criterion is auditable.
• Re-verify at the start of each quarter and whenever a denial cites a criterion the team does not recognize.

Back to guide navigation

13

GoHealthcare MSK Specialty Procedure Library™

CMS Prior Authorization Program for Certain Hospital Outpatient Department Services

Implanted spinal neurostimulators were added to the nationwide prior authorization program for certain hospital outpatient department services effective July 1, 2021. This program is distinct from WISeR, applies in every state, and applies only in the hospital outpatient department setting. It is the single most commonly misapplied program in neuromodulation revenue cycle.

Program Attribute	Detail
Codes in scope	CPT® 63650 only. CPT® 63685 and 63688 were temporarily removed from the list and do not currently require prior authorization under this program.
Setting	Hospital outpatient department only. The program does not apply to ambulatory surgery centers or physician offices.
Trial and permanent, both in the OPD	A provider performing both the trial and the permanent implantation using CPT® 63650 in the hospital outpatient department submits a prior authorization request for the trial procedure only. The Unique Tracking Number issued for the trial must then be placed on the claim for the permanent implantation procedure.
Trial performed outside the OPD	Where the trial is performed in an ambulatory surgery center or office and the permanent implantation is performed in the hospital outpatient department, a prior authorization request must be submitted for CPT® 63650 as part of the permanent implantation procedure.
Documentation for permanent placement	All trial-stage documentation plus documentation of pain relief with the temporary implanted electrode. A successful trial is described as associated with at least a 50 percent reduction of target pain or a 50 percent reduction of analgesic medications.
Unique Tracking Number	The UTN must appear on the associated claim. Omission of the UTN is a mechanical claim failure that is entirely preventable and is a leading cause of avoidable denial in hospital outpatient neuromodulation.
Interaction with WISeR	WISeR expressly excludes codes already subject to prior authorization under existing CMS programs. CPT® 63650 therefore remains in the OPD program and is not routed to a WISeR participant.
Reference	https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-program s/prior-authorization-pre-claim-review-initiatives/prior-authorization-certain-hospital-outpatient-depar tment-opd-services

The Two-Site Trap

The most expensive recurring error in this program arises when the trial is performed in the ASC or office and the permanent implantation is performed in the hospital outpatient department. Teams accustomed to the single-site rule assume that because the trial was authorized, or because no authorization was required in the ASC, the permanent implantation is covered. It is not. A separate prior authorization request for CPT® 63650 is required as part of the permanent implantation in the hospital outpatient department, and the resulting UTN must appear on the facility claim.

• Establish a hard scheduling rule: any change in site of service between trial and permanent implantation triggers an authorization re-review before the case is booked.
• Track the UTN as a required field in the case record, owned by a named person, not as a note in a scheduling comment.
• Reconcile UTNs against booked cases weekly, before the claim drops.

Back to guide navigation

14

GoHealthcare MSK Specialty Procedure Library™

The WISeR Model: Technology-Enhanced Prior Authorization in Original Medicare

The Wasteful and Inappropriate Service Reduction Model, administered by the Center for Medicare and Medicaid Innovation, launched on January 1, 2026 and runs through December 31, 2031. It introduces prior authorization or pre-payment medical review into Original Medicare for a defined list of items and services, using contracted technology companies that apply artificial intelligence and machine learning alongside clinical review. Electrical nerve stimulator implantation is in scope. For MSK specialty practices in the six model states, this is the most significant change to Medicare neuromodulation operations in a generation.

Model Architecture

Attribute	Detail
Authority and duration	Section 1115A of the Social Security Act. January 1, 2026 through December 31, 2031, structured as two three-year agreement periods.
Applies to	Original Medicare only. Medicare Advantage and Railroad Medicare beneficiaries are excluded.
States and MAC jurisdictions	New Jersey (JL, Novitas Solutions); Ohio (J15, CGS Administrators); Oklahoma and Texas (JH, Novitas Solutions); Arizona and Washington (JF, Noridian Healthcare Solutions).
Model participants (one per state)	Cohere Health (Texas); Genzeon (New Jersey); Humata Health (Oklahoma); Innovaccer (Ohio); Virtix Health (Washington); Zyter (Arizona).
Neuromodulation code in scope	CPT® 63655, laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural, under NCD 160.7. Prior authorization and pre-payment review are implemented for the permanent implantation procedure only.
Expressly excluded	CPT® 63650, because it is already subject to the CMS Prior Authorization Program for Certain Hospital Outpatient Department Services.
Other neurostimulation categories in scope	Vagus nerve stimulation (64568, initial implantation); phrenic nerve stimulator (33276, 33277); sacral nerve stimulation for urinary incontinence (64561 and 64581, and only when 64561 is billed in conjunction with generator code 64590); induced lesions of nerve tracts (64605, 64610).
Delayed	Deep brain stimulation (NCD 160.24) and percutaneous image-guided lumbar decompression (NCD 150.13). Both to be reevaluated in a future performance year.
Sites of service	Hospital outpatient department (TOB 13X; POS 19 and 22), ambulatory surgery center (POS 24), home (POS 12), and office (POS 11). In the hospital OPD and ASC settings, WISeR selects facility-based encounters and claims rather than professional services.
Two pathways	Submit a prior authorization request in advance, or furnish the service and submit the claim without prior authorization, in which case the claim is suspended and routed for pre-payment medical review.
Standard determination timeframe	3 calendar days from receipt of the initial or resubmitted request.
Expedited determination timeframe	2 calendar days where delay could seriously jeopardize the beneficiary's life, health, or ability to regain maximum function. If the participant does not confirm the risk, the request reverts to the standard timeframe with notice.
Pre-payment review timeframe	45 calendar days for the provider to respond to the documentation request; determination to the MAC within 3 days of receipt of all documentation. Failure to respond within 45 days results in claim denial.
Validity period	A provisional affirmation and its Unique Tracking Number are valid for 120 calendar days from the decision date. Services not delivered within the window require a new request.
Decision types	Provisional affirmation; non-affirmation; provisional partial affirmation (effective April 1, 2026); and dismissal. Non-affirmations require review by a human clinician with relevant clinical expertise before issuance.
Resubmission and peer-to-peer	Unlimited resubmissions are permitted. Peer-to-peer clinical review may be requested with a resubmission and connects the provider to a clinician with specialty expertise in the condition under review.
Appeals	A non-affirmation is not an initial determination and is therefore not itself appealable. Rendering the service and receiving a claim denial creates an initial determination and full Medicare appeal rights. All standard Medicare appeal rights are preserved.

Attribute	Detail
Exemption program	Providers may earn Exemption Status by submitting at least 10 prior authorization requests across WISeR select items and services during an assessment period and achieving a minimum affirmation threshold. Notifications began in June 2026 and are issued quarterly. Exempt providers are reevaluated through a limited number of additional documentation requests annually and receive at least 60 days' notice before loss of status.
Claim exclusions	Veterans Affairs, Indian Health Services, Medicare Advantage, Part A and Part B rebilling, and emergency department claims submitted with the ET modifier or a 045x revenue code.
Associated services	Anesthesia, implanted devices, physician services, and facility services associated with a non-affirmed or denied primary service will also be denied. This is the single largest financial exposure in the model.
Reference	WISeR Provider and Supplier Operational Guide, Version 6.0, last updated April 24, 2026. https://www.cms.gov/files/document/wiser-provider-supplier-guide.pdf

WISeR Documentation Expectations for Permanent Paddle Implantation (CPT® 63655)

The operational guide sets out the documentation the model participant expects for laminectomy implantation of a spinal cord stimulator paddle electrode. These expectations are drawn from NCD 160.7 and do not create new obligations, but they are far more explicit than the NCD text and should be treated as the working standard.

• Documentation of the condition requiring the procedure and the applicable physical examination
• Documentation that stimulation is being used only as a late resort, if not a last resort, including at least one of the following tried and failed, or documented as contraindicated: medications, physical therapy, injections, spine surgery, or cognitive behavioral therapy
• Documentation that the patient was evaluated by a multidisciplinary team, including psychological, surgical, medical, and physical therapy evaluation
• Documentation that the patient achieved a demonstrated 50 percent reduction in pain and evidence of functional restoration with a temporarily implanted electrode
• Documentation that the patient is not a candidate for percutaneously placed leads — for example prior instrumentation, challenging anatomy, elevated body mass index, or other technical challenges

GoHealthcare Prior Authorization Insight: The Paddle Rationale Is the Whole Case

Of the five WISeR documentation expectations for CPT® 63655, four will already be present in a competently prepared neuromodulation packet. The fifth — the affirmative statement that the patient is not a candidate for percutaneous lead placement — is the one that is routinely absent, because it is a technical surgical judgment that physicians make silently and rarely write down.

• Add a required field to the operative planning note: Rationale for open paddle approach in lieu of percutaneous placement.
• Acceptable content includes prior surgical instrumentation at or adjacent to the target level, documented epidural fibrosis, failed prior percutaneous attempt, anatomic stenosis precluding safe access, elevated body mass index affecting lead stability, or documented lead migration history.
• Corroborate with the imaging finding or operative history that supports the judgment. A bare assertion is weaker than a two-sentence explanation tied to a study.
• This single field is, in our experience, the highest-yield template change available to a practice operating in a WISeR state.

WISeR Strategic Considerations for 2026

• Prior authorization is voluntary; consequences are not. A practice that declines to submit is electing pre-payment review on every claim, with a 45-day documentation clock and cash flow held in suspense. For an implantable-device service line, that is rarely the better economics.
• Pursue Exemption Status deliberately. The threshold requires at least 10 requests across WISeR select items and services plus a minimum affirmation rate. Programs that submit early, submit complete packets, and hold a high first-pass affirmation rate can exit the program prospectively. Programs that submit thin packets and accumulate non-affirmations may not.
• Protect the affirmation rate from the start. Because exemption is threshold-based, early non-affirmations carry disproportionate cost. Consider a mandatory internal pre-submission review for the first cohort of requests.
• The 120-day window is a scheduling constraint. Affirmed cases must be delivered within 120 days of the decision date. Build the expiration date into the surgical scheduling record.
• Associated services follow the primary. Anesthesia, device, physician, and facility claims are denied when the primary service is non-affirmed or denied. Model the full episode exposure, not the facility fee alone.
• Use the peer-to-peer. It is available with resubmission, connects to a clinician with relevant specialty expertise, and is anchored to the NCD or LCD plus the published documentation requirements. Prepare for it against those documents specifically.
• Expect geographic expansion. CMS may update the select items and services list during the performance period. Practices outside the six states should build to WISeR documentation standards now rather than retrofit later.

Back to guide navigation

15

GoHealthcare MSK Specialty Procedure Library™

Commercial Payer and Utilization Management Comparison

Commercial coverage for neuromodulation is administered largely through delegated utilization management vendors, and the vendor criteria set frequently matters more than the health plan name on the member's card. The same employer-sponsored plan may delegate musculoskeletal review to one vendor and retain review for another service line. The first operational question is therefore never "what does this payer cover" but "who reviews this, and under which document version."

The summaries below are synthesized descriptions of publicly available criteria structures, prepared for educational purposes. No proprietary payer policy language is reproduced. Practices must review the current source document for the specific member's plan before relying on any characterization here. At least one vendor's published guidelines expressly restrict use of the guidelines by external artificial intelligence entities without written permission; organizations building automated tooling on payer criteria should obtain legal review before doing so.

Utilization Management Vendors

Vendor	Neuromodulation Posture and Operational Notes
eviCore by Evernorth	Guideline CMM-211, Spinal Cord and Dorsal Root Ganglion Stimulation, with a V1.0.2026 version effective August 4, 2026; intrathecal systems are addressed in CMM-210. The criteria structure is indication-specific with separate trial and permanent-implant gates. Covered indications are narrow: persistent pain after spinal surgery, CRPS/RSD of the extremities, chronic critical limb ischemia, and chronic stable angina. Requires failure of approximately six consecutive months of physician-supervised conservative management, a behavioral health attestation, a trial exceeding 48 hours, and at least 50 percent pain reduction for permanent implantation. A repeat trial after a failed trial is treated as not medically necessary. High-frequency stimulation is limited to the post-surgical indication. Critical divergences: DRG stimulation is treated as not medically necessary except for replacement of an existing DRG system; peripheral nerve stimulation and peripheral nerve field stimulation are treated as experimental, investigational, or unproven; peripheral neuropathy including painful diabetic neuropathy is listed among non-covered indications; and generator modes other than tonic-low and high frequency are addressed restrictively. Verify the version in effect on the date of service.
Carelon Medical Benefits Management	Interventional Pain Management Clinical Appropriateness Guidelines, with a revision effective June 14, 2026, containing a dedicated Spinal Cord and Dorsal Root Ganglion Stimulators section. Carelon applies a common framework across interventional pain: conservative management defined as physical therapy plus at least one complementary modality; symptom severity defined by a pain threshold combined with inability to perform at least two activities of daily living or instrumental activities of daily living; and a requirement that imaging be performed and interpreted by an independent radiologist. For stimulators, the conservative management definition additionally incorporates minimally invasive interventional modalities such as epidural injections, facet procedures, and sympathetic blocks. 2026 changes to track: the June 14, 2026 revision added criteria for stimulator replacement, added an allowance for replacement, revision, or removal at end of service, and removed the separate "loss of effectiveness" criterion; earlier revisions removed a required disability index threshold and a required behavioral or medical health statement, and added painful diabetic neuropathy as an indication under strict criteria. Do not assume a removed requirement is removed for every plan; health plan adoption dates vary.
Cohere Health	Operates as a delegated utilization management partner for commercial and Medicare Advantage plans and is the WISeR Model participant for Texas. Emphasizes episode-level and pathway-based authorization with structured intake. Practices operating in Texas should recognize that the same organization may be reviewing their commercial and their Original Medicare requests under different rule sets.
Evolent (formerly New Century Health / National Imaging Associates)	Delegated specialty utilization management for musculoskeletal and interventional pain for a number of regional and Medicaid managed care plans. Criteria generally track specialty society and Medicare frameworks. Confirm the delegated program and submission portal at the plan level.
TurningPoint Healthcare Solutions	Delegated musculoskeletal and surgical quality programs for several regional plans and Medicare Advantage products. Frequently applies a surgical-appropriateness review posture with active peer-to-peer engagement. Where TurningPoint is delegated, expect the peer-to-peer to be substantive and to be conducted by a specialty-matched reviewer.
NaviNet and plan portals	NaviNet and comparable multi-payer portals are workflow and submission infrastructure rather than criteria sources. Confirm attachment size limits, accepted file formats, and whether the portal supports structured clinical intake before building submission templates around it.

National Commercial Payers

Payer	Neuromodulation Posture and Operational Notes
UnitedHealthcare	Maintains separate commercial and Medicare Advantage medical policies for spinal cord stimulators for chronic pain and for implanted spinal drug delivery systems. The Medicare Advantage policy tracks NCD 160.7 closely, including multidisciplinary screening with psychological as well as physical evaluation, and reflects the preference that the physician performing the trial also perform the permanent implant, with written notification to the patient identifying the referral surgeon where that is not possible. Musculoskeletal and interventional pain review may be delegated depending on product and market.
Aetna	Clinical Policy Bulletin 0194 addresses spinal cord stimulation, including dorsal root ganglion stimulation; CPB 0011 addresses peripheral electrical nerve stimulation for pain; CPB 0447 addresses CRPS treatments and cross-references CPB 0194, with the Budapest criteria applied for CRPS diagnosis; CPB 0158 addresses psychological and neuropsychological testing. For Medicare products, the bulletins are positioned as supplementing rather than superseding applicable NCDs and LCDs. Practices should submit against the correct bulletin for the specific therapy rather than defaulting to the SCS bulletin.
Cigna Healthcare	Musculoskeletal and interventional pain review is administered through eviCore criteria for many products, with Cigna-branded versions of the CMM guideline series. Confirm both the Cigna coverage policy and the applicable eviCore guideline version and effective date.
Humana	Maintains medical coverage policies for spinal cord stimulators for commercial products and separate Medicare Advantage policies that reference the applicable NCD and LCDs. Medicare Advantage determinations must follow fully established Medicare coverage criteria where they exist.
Elevance Health (Anthem) and Blue Cross Blue Shield plans	Highly variable by state licensee. Many Elevance and Blue plans delegate interventional pain and musculoskeletal review to Carelon; others maintain independent medical policies. Blue Cross Blue Shield Federal Employee Program operates under its own benefit brochure and medical policy. Never generalize from one Blue plan to another.
Molina Healthcare, Centene, and WellCare	Medicaid and Medicare Advantage focused. Criteria commonly incorporate state Medicaid coverage rules layered onto a national medical policy, and delegation to a specialty vendor is common. State Medicaid rules may impose additional requirements not present in the plan's national policy.
Kaiser Permanente	Integrated delivery model with internal utilization review. External referrals for neuromodulation typically require internal specialty concurrence in addition to medical necessity documentation.
Regional commercial and workers' compensation carriers	Frequently adopt a national vendor's criteria by reference, or apply a state workers' compensation treatment guideline. In workers' compensation, the treatment guideline and the utilization review timeline are set by state statute and may differ substantially from group health norms, including in the psychological evaluation requirement.

Where Payers Agree and Where They Diverge

Criterion	Broad Agreement	Principal Divergence
Trial before permanent implantation	Universal. A temporary trial demonstrating benefit is required before permanent implantation across Medicare and commercial payers.	Minimum trial duration and whether a repeat trial after a failed trial is ever permitted.
Trial success threshold	At least 50 percent reduction in target pain is the dominant standard; many payers accept at least 50 percent reduction in analgesic medication as an alternative.	Whether objective functional improvement must be separately documented, and on which instrument.
Psychological evaluation	Required in principle by Medicare and by most commercial criteria.	The largest divergence in the category: full psychometric testing, a narrative evaluation, or a behavioral health attestation — and at least one vendor removed its behavioral health statement requirement in a 2026 revision.
Conservative care duration	All payers require documented failure of conservative management.	Medicare imposes no fixed duration; commercial vendors commonly require six consecutive months of physician-supervised management for SCS.
Post-surgical persistent spinal pain	Covered essentially universally.	Definitional scope of what counts as prior spinal surgery; some criteria exclude procedures that did not encroach on the spinal canal.
Complex regional pain syndrome	Covered for SCS by Medicare and most commercial payers.	Anatomic restriction to the extremities; whether DRG stimulation is an available option; and whether Budapest criteria documentation is mandatory.
Painful diabetic neuropathy	FDA-approved indication with supporting randomized evidence.	The sharpest divergence. Accessible under Medicare in jurisdictions applying NCD 160.7 without restrictive diagnosis edits; added by at least one vendor under strict criteria; expressly non-covered by at least one other.
Dorsal root ganglion stimulation	FDA-approved for CRPS and causalgia of the lower extremities.	Covered by several plans under CRPS criteria; treated as not medically necessary except for replacement by at least one major vendor.
Peripheral nerve stimulation	Recognized therapy with a defined Medicare LCD and article, and dedicated CPT® codes.	Covered by some plans with SCS-analogous criteria; classified as experimental, investigational, or unproven by at least one major vendor.
Peripheral nerve field stimulation	Consensus that evidence is limited.	Effectively universal non-coverage; reported with unlisted code 64999.
High-frequency and advanced waveforms	10 kHz stimulation is FDA-approved and broadly recognized.	Whether high frequency is covered outside the post-surgical indication; whether burst and closed-loop modes are separately addressed; whether replacement of a functioning conventional system with a high-frequency system is permitted.
Replacement and revision	Covered for malfunction, end of service, and battery depletion.	Whether warranty status must be documented; whether a new trial is required; whether modality or manufacturer substitution is permitted; and whether "loss of effectiveness" survives as an independent criterion.

Back to guide navigation

16

GoHealthcare MSK Specialty Procedure Library™

Prior Authorization Workflow

The workflow below is written as an operating procedure. It assumes a two-stage therapy and treats the trial authorization and the permanent authorization as separate transactions with separate owners and separate quality gates.

Stage 0 — Candidacy Identification and Rulebook Determination

1. At the visit where neuromodulation is first discussed, open the conservative care ledger and request all outside records. Do not wait for the decision to proceed.
2. Verify eligibility and benefits, and determine the governing rulebook. Establish: is this Original Medicare, Medicare Advantage, commercial, Medicaid managed care, or workers' compensation? Is musculoskeletal or interventional pain review delegated, and to whom?
3. Determine the planned CPT® code, the planned site of service, and the state of service. Together these determine whether the CMS OPD program, the WISeR Model, or plan criteria apply.
4. Retrieve and date-stamp the governing coverage document. Record the identifier, version, and effective date in the case record.
5. Confirm the specific device and manufacturer with the implanting physician, including waveform capability, rechargeable status, and MR conditional labeling.

Stage 1 — Trial Authorization

1. Assemble Checklist A. Complete the conservative care ledger with dates, doses, and measured outcomes.
2. Obtain the psychological or behavioral health evaluation and confirm it contains an explicit suitability conclusion, not merely a description of the assessment.
3. Obtain and attach the formal radiology report, not a summary.
4. Draft the medical necessity statement against the named policy, addressing each criterion in the policy's own sequence.
5. Conduct internal pre-submission review. A second reviewer confirms every criterion is supported by an attached document and that the attachment is legible and complete.
6. Submit through the correct channel. For Original Medicare in a WISeR state, submit to the assigned model participant or to the MAC; for the hospital OPD program, submit to the MAC. For commercial, use the delegated vendor's portal.
7. Record the submission date, the reviewer, and the expected determination date. Calendar the follow-up before the clock expires.
8. On determination, record the Unique Tracking Number or authorization number, the approved codes and units, and the expiration date. Enter the expiration date into the surgical scheduling record as a hard constraint.

Stage 2 — Trial Conduct and Outcome Capture

1. Record baseline pain and function scores on named instruments immediately before the trial.
2. Provide the patient with a structured trial diary capturing daily pain scores, analgesic use, sleep, and specific functional activities.
3. At trial conclusion, record the percentage reduction in target pain and the percentage reduction in analgesic medication, using the same instruments used at baseline.
4. Record objective functional improvement with specific regained activities, not general statements.
5. Document trial dates, absence of complications, and the physician's explicit conclusion that the trial met the threshold in the applicable policy.
6. If the trial did not meet threshold, document that conclusion clearly and do not submit a permanent request. A denied permanent request following a documented sub-threshold trial damages the practice's affirmation profile and, in a WISeR state, its exemption prospects.

Stage 3 — Permanent Implantation Authorization

1. Confirm whether a separate authorization is required. Under the hospital OPD program, where both stages occur in the same hospital outpatient department, the trial UTN carries forward to the permanent claim. Where the site of service changed, a new request is required.
2. Assemble Checklist B. The trial outcome data is the centerpiece of this packet.
3. For paddle or laminectomy requests, include the affirmative rationale that the patient is not a candidate for percutaneously placed leads.
4. Reconfirm that the device selected matches the device authorized, and that MR conditional labeling still accommodates the patient's anticipated imaging needs.
5. Submit, track, and record the authorization number and expiration date.

Stage 4 — Pre-Service Reconciliation

1. Seventy-two hours before the case, reconcile the authorization number, the approved CPT® codes, laterality, levels, units, site of service, and the expiration date against the booked case.
2. Confirm the implanting physician and facility match the authorization.
3. Confirm the UTN is captured in the field that will populate the claim.
4. Confirm device availability and that the model matches what was authorized.
5. Escalate any mismatch to the physician and to scheduling before the patient arrives.

Stage 5 — Claim Submission and Post-Service Management

1. Ensure the UTN appears on the claim. For institutional claims the UTN occupies the treatment authorization field per the applicable program instructions; for professional claims it is reported in the prior authorization reference segment or, on paper, in the designated item on the claim form.
2. Confirm that associated services — anesthesia, device, physician, and facility — are aligned to the same authorized primary service.
3. Monitor for suspended claims and additional documentation requests. Under pre-payment review the response window is 45 days and non-response results in denial.
4. Track denials by reason code and by criterion, not merely by dollar amount. The criterion is what tells you which template to fix.
5. Feed every denial back into the pre-submission checklist within the same month.

Turnaround Expectations

• WISeR Model: 3 calendar days standard; 2 calendar days expedited; 120-day validity; unlimited resubmissions; peer-to-peer available with resubmission.
• Pre-payment medical review: 45 calendar days for the provider to respond to the documentation request; determination within 3 days of receipt of complete documentation.
• Commercial and Medicare Advantage: governed by plan contract and by state and federal turnaround standards. Build the internal clock to the shortest applicable standard, not the longest.
• Workers' compensation: state statutory utilization review timelines apply and are frequently shorter and less forgiving than group health timelines.

Back to guide navigation

17

GoHealthcare MSK Specialty Procedure Library™

Psychological and Behavioral Health Evaluation

The psychological evaluation is simultaneously the most consistently required and the most inconsistently specified element in neuromodulation authorization. NCD 160.7 conditions coverage on multidisciplinary screening that includes psychological as well as physical evaluation. WISeR documentation expectations name psychological evaluation explicitly among the multidisciplinary elements. Commercial requirements range from formal psychometric testing to a behavioral health attestation, and at least one major vendor removed its behavioral or medical health statement requirement during a 2026 revision cycle.

What a Defensible Evaluation Contains

• Identification of the evaluating clinician, credentials, date, and modality (in person or virtual).
• Structured clinical interview findings addressing mood, anxiety, trauma history, catastrophizing, coping style, and pain beliefs.
• Screening for substance use disorder, including current opioid use and any aberrant use behaviors, with a management plan where present.
• Assessment of cognitive capacity to operate, charge, and troubleshoot the device, and to report problems.
• Assessment of social support and caregiver availability where relevant.
• Assessment of expectations, including whether the patient understands that partial relief is a realistic and successful outcome.
• Where used, named psychometric instruments with scores and interpretation.
• An explicit suitability conclusion. The report must state whether the patient is an appropriate candidate, and where concerns exist, whether they are modifiable and what remediation is recommended.

GoHealthcare Prior Authorization Insight: Conditional Clearance Is Not a Denial Trigger

Teams frequently delay or suppress a psychological evaluation that identifies modifiable concerns, fearing it will cause a denial. In practice the opposite is true. A report that identifies a concern, states that it is modifiable, recommends specific remediation, and is followed by documentation that remediation occurred is substantially stronger than a two-line clearance note. It demonstrates that the multidisciplinary screening required by NCD 160.7 actually happened.

• Build a standing referral relationship with a psychologist experienced in pre-implantation evaluation. Ad hoc referrals produce reports that do not address coverage criteria.
• Provide the evaluator with a template listing the elements payers look for, including the explicit suitability conclusion.
• Where a concern is identified, document the remediation and re-evaluation before submitting, and include both reports.
• Never submit "psych cleared" as the entirety of the evidence. It satisfies no criteria set and invites a request for records that delays the case by weeks.

Back to guide navigation

18

GoHealthcare MSK Specialty Procedure Library™

Trial-to-Permanent Conversion: Documentation That Determines the Outcome

The trial is the hinge of the entire authorization. It is the only coverage condition in NCD 160.7 that generates new evidence rather than summarizing history, and it is the element most often documented in language that cannot survive

review.

Element	Insufficient	Defensible
Pain reduction	"Patient reports good relief."	"Baseline NRS 8/10 on 03/04; trial NRS 3/10 on 03/09, a 62 percent reduction in target low back and left leg pain, sustained across the five-day trial per daily diary."
Analgesic reduction	"Decreased pain medication."	"Oxycodone reduced from 30 mg to 10 mg daily morphine milligram equivalents during trial, a 67 percent reduction, without breakthrough dosing."
Functional improvement	"Improved function."	"Oswestry Disability Index 62 at baseline, 38 at trial conclusion. Patient ambulated in the community for 25 minutes without rest versus 5 minutes at baseline, and slept through the night on four of five trial nights versus zero at baseline."
Instrument consistency	Baseline measured with VAS, trial measured with NRS.	Same named instrument at baseline and at trial conclusion, with both values in the same note or explicitly cross-referenced.
Trial conduct	"Trial performed."	Placement date, removal date, number of leads, target levels, absence of complications, and the physician's explicit conclusion that the threshold in the named policy was met.
Threshold statement	Left for the reviewer to infer.	"This trial meets the requirement of at least 50 percent reduction in target pain together with objective functional restoration."

A trial diary is the least expensive and highest-return tool in the neuromodulation packet. It converts a recollected impression into contemporaneous, dated, patient-reported data, and it is what allows a peer-to-peer reviewer to affirm without requesting additional records.

Back to guide navigation

19

GoHealthcare MSK Specialty Procedure Library™

Device Manufacturers and System Considerations

Device selection has direct authorization and downstream consequences. Waveform capability determines which indications a system can support; rechargeable status affects longevity and replacement frequency; MR conditional labeling determines whether the patient can undergo future imaging; and the physical architecture of the system — integrated single-component versus two-component with a separate pulse generator — determines which CPT® code family applies.

Principal Manufacturers by Therapy Family

Therapy	Manufacturers and Representative Systems	Authorization-Relevant Attributes
Spinal cord stimulation	Medtronic (Intellis, Vanta, Inceptiv); Abbott (Proclaim, Eterna, with BurstDR stimulation); Boston Scientific (WaveWriter Alpha); Nevro (Senza/HFX platform, 10 kHz); Saluda Medical (Evoke, evoked-compound-action-potential closed loop).	Waveform capability (tonic, 10 kHz high frequency, burst, closed loop) drives indication eligibility and is a direct coverage issue where a criteria set limits high frequency to a specific indication or addresses non-tonic modes restrictively. Rechargeable versus non-rechargeable (recharge-free) selection affects patient burden and replacement interval. MR conditional status varies by system, lead configuration, and scan region.
Dorsal root ganglion stimulation	Abbott Proclaim DRG, the sole FDA-approved DRG neurostimulation system in the United States.	Because a single approved system exists, a DRG denial is a therapy denial. There is no alternative-device pathway. Approvals rest on the CRPS or causalgia indication and on the argument that dorsal column stimulation is not clinically substitutable.
Peripheral nerve stimulation	SPR Therapeutics (SPRINT, a temporary 60-day system); Nalu Medical; Curonix (formerly Stimwave, Freedom platform); Bioness/StimRouter.	The temporary versus permanent distinction is central. Integrated single-component systems map to the integrated-neurostimulator code family; two-component systems requiring pocket creation and a detachable connection map to the separate lead and generator codes. Confirm the FDA product classification and the labeled indication before coding.
Intrathecal drug delivery	Medtronic (SynchroMed II, SynchroMed III); Flowonix (Prometra II).	Coverage is conditioned on the specific agent and concentration and on labeling. Refill and reprogramming services carry their own frequency expectations. MRI protocols for implanted pumps are system-specific and require pre-scan and post-scan management.
Sacral nerve stimulation	Medtronic InterStim platform; Axonics.	Trial versus permanent distinction governs both coding and, in WISeR states, whether prior authorization applies. Rechargeable and recharge-free options differ in replacement interval.

MRI Conditionality: An Underused Documentation Element

MR conditional labeling is generally treated as a clinical consent topic. It is also an authorization and patient-satisfaction issue. A patient with degenerative spine disease, a cancer history, or a neurological condition is likely to require future magnetic resonance imaging. Documenting the anticipated imaging need, the selected system's MR conditional labeling, and the reconciliation between the two strengthens the medical necessity narrative and materially reduces post-implant dissatisfaction and explant risk.

• Document the patient's anticipated MRI needs by body region, not merely as a yes-or-no.
• Confirm the specific system's MR conditional labeling, including whether conditionality extends to full-body scanning and whether it depends on lead configuration.
• Where a conflict exists, document the discussion and the rationale for the selected system.
• Provide the patient with device identification materials and confirm that the record reflects the implanted model, not the model originally planned.

Regulatory note: neurostimulation labeling, indications, and MR conditionality change with each device generation and with post-market labeling supplements. Manufacturer claims in this guide should be verified against current FDA-cleared or FDA-approved labeling and current manufacturer MRI guidelines before being relied upon clinically. Verify at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm and against the manufacturer's current instructions for use.

Back to guide navigation

20

GoHealthcare MSK Specialty Procedure Library™

Coding Snapshot

This section provides an operational coding overview sufficient to route authorizations correctly and to align documentation with code selection. It does not address reimbursement methodology, fee schedules, payment rates, NCCI edit tables, or medically unlikely edit values, which belong to the GoHealthcare Revenue Cycle Knowledge Center.

Spinal Neurostimulator Codes

Code	Descriptor Summary	Operational Note
63650	Percutaneous implantation of neurostimulator electrode array, epidural	Used for both the temporary trial and percutaneous permanent lead placement. Subject to the CMS Prior Authorization Program for Certain Hospital OPD Services. Expressly excluded from WISeR.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural	The open surgical paddle approach. The WISeR Model electrical nerve stimulator code. Requires documented rationale that percutaneous placement is not appropriate.
63661	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy when performed	Fluoroscopy is included in the descriptor.
63662	Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy when performed
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy when performed
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminectomy, including fluoroscopy when performed
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver	Two-component architecture. Not reported with 63688 for the same generator. Currently not subject to OPD prior authorization.
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array	Currently not subject to OPD prior authorization.

Peripheral, Sacral, and Integrated System Codes

Code	Descriptor Summary	Operational Note
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	Reports the electrode array for both trial and permanent placement in a two-component system. Used per lead.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement), including image guidance if performed	In WISeR states, subject to prior authorization only when billed in conjunction with generator code 64590. Trial placement and lead replacement alone are not subject to WISeR.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)	In scope for WISeR under NCD 230.18.
64585	Revision or removal of peripheral neurostimulator electrode array	Used for revision or removal of the electrode array only.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver	Two-component architecture. Used in conjunction with 64555 or 64561 for permanent placement. Not reported with 64595, 64596, 64597, or 64598.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance when performed; initial electrode array	Integrated single-component architecture. Imaging guidance is included. Not reported with 64555, 64561, 64590, or 64595.
64597	each additional electrode array (add-on)	Reported in conjunction with 64596.
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator
64999	Unlisted procedure, nervous system	The reporting pathway for peripheral nerve field stimulation and subcutaneous field stimulation, and for neurostimulators without a named target nerve. Expect manual review, and submit a narrative description with the claim.

Category III and Programming Codes

Code	Descriptor Summary
0784T / 0785T	Insertion or replacement / revision or removal of percutaneous electrode array, spinal, with integrated neurostimulator
0786T / 0787T	Insertion or replacement / revision or removal of percutaneous electrode array, sacral, with integrated neurostimulator
0788T / 0789T	Electronic analysis with simple (1-3 parameters) or complex (4 or more parameters) programming of an implanted integrated neurostimulation system, spinal cord or sacral nerve
0587T–0590T	Percutaneous implantation, revision or removal, electronic analysis, and programming of an integrated tibial nerve neurostimulation system for bladder dysfunction
0816T / 0817T / 0818T / 0819T	Open implantation or replacement, and revision or removal, of an integrated posterior tibial nerve neurostimulator system
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming
95971 / 95972	Electronic analysis with simple (1-3 parameters) or complex (4 or more parameters) programming, spinal cord or peripheral nerve
95976 / 95977	Electronic analysis with simple or complex programming, cranial nerve
95983 / 95984	Electronic analysis with brain neurostimulator programming, time-based reporting

Electronic analysis is inherent to the implantation codes and is not separately reported at the time of implantation. Several LCDs and articles treat programming services more frequently than once every 30 days as not medically necessary. Simple programming adjusts one to three parameters; complex programming adjusts more than three. A single parameter adjusted multiple times in one session counts once.

Intrathecal Drug Delivery Codes

Code	Descriptor Summary
62350 / 62351	Implantation, revision, or repositioning of a tunneled intrathecal or epidural catheter for implantable pump or reservoir, without / with laminectomy
62355	Removal of previously implanted intrathecal or epidural catheter
62360 / 62361 / 62362	Implantation or replacement of a device for intrathecal or epidural drug infusion: subcutaneous reservoir; non-programmable pump; programmable pump, including preparation of the pump, with or without programming
62365	Removal of a subcutaneous reservoir or pump previously implanted for intrathecal or epidural infusion
62367–62370	Electronic analysis of a programmable implanted pump, with or without reprogramming and refill
95990 / 95991	Refilling and maintenance of an implantable pump or reservoir for drug delivery, spinal or brain

Common ICD-10-CM Diagnosis Codes

The codes below are representative and must be selected to the highest available specificity and verified against the applicable billing and coding article for the practice's jurisdiction. Diagnosis-to-procedure edits published in those articles drive automated denials.

Category	Representative Codes
Post-laminectomy syndrome	M96.1 (postlaminectomy syndrome, not elsewhere classified); G89.4 (chronic pain syndrome); G89.28 / G89.29 (other chronic postprocedural pain / other chronic pain)
Complex regional pain syndrome	G90.511–G90.513 (CRPS I of upper limb, right/left/bilateral); G90.521–G90.523 (CRPS I of lower limb); G90.529 (CRPS I of unspecified lower limb); G90.59 (CRPS I of other specified site); G56.41–G56.43 (causalgia of upper limb); G57.71–G57.73 (causalgia of lower limb)
Radiculopathy and radicular pain	M54.16–M54.17 (radiculopathy, lumbar region / lumbosacral region); M54.12 (radiculopathy, cervical region); M54.4x (lumbago with sciatica); M54.3x (sciatica)
Diabetic neuropathy	E11.40–E11.49 (type 2 diabetes mellitus with neurological complications, including E11.42 polyneuropathy); E10.40–E10.49 (type 1); E08.4x, E09.4x, E13.4x (secondary and drug- or chemical-induced diabetes with neurological complications)
Other neuropathic pain	G58.9 (mononeuropathy, unspecified); G62.9 (polyneuropathy, unspecified); G54.6 / G54.7 (phantom limb syndrome with / without pain); B02.29 / B02.23 (post-herpetic neuralgia); G89.21 (chronic pain due to trauma)
Ischemic and cardiac indications	I70.22x / I70.23x (atherosclerosis of native arteries of extremities with rest pain / ulceration); I73.9 (peripheral vascular disease, unspecified); I20.8 / I20.9 (other and unspecified angina pectoris); I25.11x (atherosclerotic heart disease with angina pectoris)
Malignancy and spasticity (intrathecal)	G89.3 (neoplasm related pain, acute or chronic); C-series primary and secondary malignancy codes; G80.x (cerebral palsy); G35 (multiple sclerosis); G81.x / G82.x (hemiplegia, paraplegia, quadriplegia)
Device complications	T85.113A–T85.199A (breakdown, displacement, or other mechanical complication of implanted electronic nervous system stimulator); T85.192A (other mechanical complication of implanted electronic neurostimulator); T85.79xA (infection and inflammatory reaction due to other internal prosthetic devices); Z45.42 (encounter for adjustment and management of implanted nervous system device)

Modifiers, Place of Service, and ASC Considerations

Element	Application in Neuromodulation
Modifier 22	Increased procedural services. Requires a separate operative narrative quantifying the additional work. Use sparingly and support substantively.
Modifier 50 / RT / LT	Bilateral and laterality reporting. Payer preference varies between modifier 50 and separate RT/LT lines; confirm plan convention.
Modifier 51 / 59 / XS / XU	Multiple and distinct procedural services. Apply only where the applicable edit and documentation genuinely support separate reporting.
Modifier 58 / 78 / 79	Staged or related procedure, unplanned return to the operating room, and unrelated procedure during the postoperative period. Directly relevant to the two-stage trial-to-permanent pathway and to revisions occurring within a global period.
Modifier GA / GX / GZ / GY	Advance Beneficiary Notice and liability modifiers. Under WISeR, a non-affirmed determination on medical necessity grounds should prompt issuance of an ABN in advance of performing the service, with the claim submitted appending GA. GX applies where an ABN is issued voluntarily for a statutorily excluded service.
Modifier 62 / 80 / 82	Co-surgeon and assistant surgeon reporting, most relevant to open paddle implantation.
POS 11	Office. In scope for WISeR sites of service. Common for temporary PNS and some trial procedures.
POS 19 / 22	On-campus and off-campus hospital outpatient department. The setting in which the CMS OPD prior authorization program applies to CPT® 63650.
POS 24	Ambulatory surgery center. The OPD prior authorization program does not apply here; WISeR does, for facility claims, in model states.
ASC considerations	Confirm that the planned code is on the ASC covered procedures list and that device cost is appropriately accounted for under the applicable device-intensive methodology. Confirm which entity holds the authorization obligation. In the hospital OPD and ASC settings under WISeR, the model selects facility-based encounters and claims, and the UTN belongs on the facility claim.

General Coding Considerations and Pitfalls

• Integrated versus two-component architecture. The single most consequential coding decision. Integrated single-component systems map to 64596–64598 or the corresponding Category III codes. Two-component systems requiring pocket creation and a detachable connection map to the separate array and generator codes. The operative note must describe the architecture that supports the code reported.
• Named target nerve. Where there is no named target nerve, the service is field stimulation and is reported with 64999, not with a peripheral nerve code.
• Trial and permanent share a code in SCS. CPT® 63650 covers both the temporary trial and percutaneous permanent lead placement. The record, not the code, distinguishes them. State clearly in the operative note and on the authorization request whether the procedure is a trial or a permanent placement.
• Bundled fluoroscopy and imaging guidance. Fluoroscopy is included in the descriptors of the lead removal and revision codes and imaging guidance is included in several integrated-system codes. Do not report separately.
• Programming at implantation. Electronic analysis is inherent to the implantation codes and is not separately reportable on the day of implantation.
• Units and laterality. Report lead codes per lead where the descriptor supports it, and ensure the authorization reflects the same units and laterality that will be billed.
• Device and supply reporting. Facility device reporting requirements differ between the hospital outpatient and ASC settings; confirm HCPCS device coding requirements with the facility.
• Authorization-to-claim alignment. The most common mechanical denial in this category is a claim that does not match the authorization on code, laterality, units, site of service, or performing physician. Reconcile before the case, not after the denial.

Back to guide navigation

21

GoHealthcare MSK Specialty Procedure Library™

Common Prior Authorization Denials

Denial Reason	Root Cause	Prevention
Conservative management not documented or insufficient duration	Care occurred across multiple providers and years and was never assembled into an itemized, dated record with outcomes.	Maintain the standing conservative care ledger from the first pain visit. Request outside records at candidacy identification.
Psychological evaluation absent, incomplete, or lacking a suitability conclusion	A brief clearance note was submitted, or the evaluation addressed diagnosis rather than candidacy.	Use a standing evaluator relationship and a template that requires an explicit suitability conclusion.
Trial outcome not quantified	The note records impression rather than percentage change on a named instrument.	Mandate baseline and post-trial scores on the same instrument, plus a trial diary.
Functional improvement not documented separately from pain reduction	Only a pain score was captured.	Capture a validated function instrument at baseline and at trial conclusion, plus concrete regained activities.
Indication not covered under the applicable policy	The therapy was requested for an indication the criteria set lists as not medically necessary or investigational, most often peripheral neuropathy, DRG stimulation, peripheral nerve stimulation, or field stimulation.	Confirm the indication against the governing document before scheduling and set physician expectations at intake. Where the indication is excluded, plan the medical exception or appeal pathway deliberately.
No documented rationale for the open paddle approach	The technical surgical judgment was made but not written down.	Add a required rationale field to the operative planning note. This is the single highest-yield template change in WISeR states.
Wrong policy or wrong program invoked	The request was submitted under an SCS policy for a PNS procedure, or routed to WISeR for a code excluded from WISeR.	Determine the rulebook at Stage 0 using code, state, and site of service.
Missing or incorrect Unique Tracking Number	The UTN was never captured, or the site of service changed between trial and permanent implantation without a new request.	Treat the UTN as a required case field with a named owner and reconcile weekly.
Authorization expired before the service was delivered	The 120-day WISeR validity window or the plan's validity period lapsed during scheduling delays.	Enter the expiration date into the surgical scheduling record as a hard constraint.
Imaging not submitted or not correlated	The note referenced imaging that was never attached, or the finding did not correspond to the clinical syndrome.	Attach the formal radiology report and state the concordance explicitly in the medical necessity statement.
Repeat trial after a failed trial	A second trial was requested after a documented sub-threshold first trial.	Recognize that several criteria sets treat this as not medically necessary. Where extenuating circumstances exist, document them at the time of the first trial failure, not retrospectively.
Replacement request lacking failure documentation	Warranty status, malfunction evidence, or prior therapeutic benefit was not documented.	Use Checklist C. Capture interrogation findings and warranty status at the time the failure is identified.
Associated services denied	Anesthesia, device, physician, or facility claims followed a non-affirmed or denied primary service.	Do not proceed on a non-affirmed primary service without a deliberate financial decision and, where appropriate, an ABN.

Back to guide navigation

22

GoHealthcare MSK Specialty Procedure Library™

Appeal Strategies and Peer-to-Peer Preparation

Diagnose the Denial Before Responding

Appeals fail when they argue clinical merit against an administrative denial, or administrative technicality against a clinical denial. The first step is always to classify the denial.

Denial Type	Signature	Correct Response
Administrative or mechanical	Missing UTN, expired authorization, code or laterality mismatch, wrong submission channel, missing attachment.	Correct and resubmit. Under WISeR, resubmission is unlimited. Do not construct a clinical argument for a clerical failure.
Documentation gap	The denial cites a criterion the record actually satisfies but does not clearly evidence.	Supply the specific missing document, plus a cover statement mapping each cited criterion to a page and date. This is the most common and most winnable category.
Criteria interpretation	The denial applies a criterion the record addresses differently, for example the sufficiency of conservative care duration or of the psychological evaluation format.	Request peer-to-peer. Argue against the specific policy language, with citations to the record and to specialty society guidance where the policy is silent.
Categorical non-coverage	The indication or therapy is listed as not medically necessary or investigational in the applicable criteria set.	A first-level appeal on medical necessity will rarely succeed. Pursue the medical exception or medical necessity review pathway, external review where available, and escalate to the plan's medical policy team. Where the plan is Medicare Advantage, confirm whether fully established Medicare criteria govern instead.
Post-payment or pre-payment review denial	The claim was suspended or recovered after the service was rendered.	Use the standard Medicare appeals process. Note that under WISeR a non-affirmation is not itself appealable, but a resulting claim denial is an initial determination carrying full appeal rights.

Building the Appeal

1. Quote the denial rationale verbatim in the appeal and address each cited element in the denial's own order. Reviewers work from their own rationale.
2. Map each criterion to a specific document, page, and date. Do not require the reviewer to search.
3. Attach only what is responsive. A 400-page record dump reduces the probability that the decisive document is read.
4. Include a physician attestation that speaks to the specific criterion in dispute, not a general endorsement of the therapy.
5. Where the policy is silent, cite specialty society guidance from ASIPP, ASRA, ASPN, NASS, or NANS, and identify the guidance by name and year.
6. Where the policy conflicts with FDA-approved labeling, state the conflict explicitly and attach the labeling.
7. For Medicare Advantage denials, state whether fully established Medicare coverage criteria exist and, where they do, that they govern.
8. Track the appeal deadline from the date on the determination letter, not the date received.

Peer-to-Peer Preparation

The Fifteen-Minute Peer-to-Peer Brief

A peer-to-peer is won in preparation, not in conversation. Provide the physician with a single-page brief before the call. In our experience the difference between a prepared and an unprepared peer-to-peer is the single largest controllable variable in neuromodulation overturn rates.

• Line 1: Patient, requested procedure and codes, denial date, and the exact denial rationale quoted.
• Line 2: The governing policy by name, identifier, version, and effective date.
• Block 1: Each cited criterion with the one-sentence record fact that satisfies it and the chart location.
• Block 2: The trial data — baseline score, post-trial score, percentage change, analgesic change, function change, instrument name.
• Block 3: The one or two points genuinely in dispute, with the strongest available support.
• Block 4: The ask, stated plainly — the specific codes, levels, laterality, site of service, and device requested.
• Logistics: Confirm the physician's availability window before requesting the call, and confirm whether the reviewer will be specialty-matched. Under WISeR, peer-to-peer is requested with a resubmission and connects to a clinician with specialty expertise in the condition under review.

Back to guide navigation

23

GoHealthcare MSK Specialty Procedure Library™

GoHealthcare Clinical Insights

The recommendations below reflect GoHealthcare's operational experience supporting musculoskeletal specialty practices, ambulatory surgery centers, and hospital-based neuromodulation programs. They address the workflow, documentation, and communication failures that produce denials in otherwise appropriate cases.

Documentation Quality

• Write for the reviewer, not for the chart. The clinical note serves two audiences. Structure it so a reviewer encountering it cold can locate diagnosis, duration, refractoriness, screening, and trial outcome without inference.
• Quantify everything that can be quantified. Percentages and instrument scores survive review; adjectives do not.
• Use the same instrument twice. The single most common quantification failure is measuring baseline on one scale and follow-up on another, which makes change unquantifiable.
• Eliminate copy-forward in the pain and function fields. Identical scores across twelve months undermine the credibility of the entire record, including the elements that are accurate.
• Document contraindications affirmatively. Where a policy enumerates conditions that must be absent, state that they were assessed and are absent. Silence reads as an unperformed assessment.

Workflow Improvement

• Separate the rulebook determination from the packet assembly. These are different skills. A single competent person should own "which rules apply" for the practice, and should own the quarterly re-verification of coverage documents.
• Make the pre-submission review mandatory and independent. The person who assembled the packet should not be the person who clears it. This one control produces the largest measurable improvement in first-pass approval rate.
• Treat the trial and permanent authorizations as separate transactions. They have different checklists, different evidence, and, in some programs, different requirements. Combining them in one work item is how trial data goes uncaptured.
• Build expiration dates into scheduling, not into a spreadsheet. Authorization lapse during a scheduling delay is entirely preventable and entirely self-inflicted.
• Institute a hard rule for site-of-service changes. Any change between trial and permanent implantation triggers authorization re-review before the case is booked.

Prior Authorization Success

• Name the policy in the request. Submissions that identify the governing document by name, identifier, version, and effective date, and that address criteria in the document's own sequence, are reviewed faster and approved more often.
• Front-load the packet. Place the medical necessity statement first, then the trial data, then the supporting documents in the order the criteria appear. Reviewers work under time pressure.
• Submit complete or do not submit. An incomplete submission that generates a non-affirmation is worse than a two-day delay, particularly where affirmation rate affects exemption eligibility.
• Use expedited review honestly. Reserve it for cases where delay genuinely jeopardizes life, health, or the ability to regain maximum function. Under WISeR, an unsupported expedited request is reclassified to the standard

timeframe, costing time rather than saving it.

Denial Prevention and Communication

• Close the loop between denial and template within thirty days. A denial that does not change a template will recur.
• Give physicians denial feedback by criterion, not by volume. "Three denials this month" changes nothing. "Three denials for absent paddle rationale" changes a template.
• Set patient expectations at candidacy, not at denial. Where the indication is categorically excluded by the applicable criteria set, say so at the first conversation.
• Establish a standing channel between the authorization team and the implanting physicians. The technical details that decide these cases — device architecture, approach rationale, waveform — live only in the physician's head unless someone asks.

Back to guide navigation

24

GoHealthcare MSK Specialty Procedure Library™

GoHealthcare Leadership Perspective

Neuromodulation is a strategic service line with an administrative cost structure that most organizations underestimate. The financial profile is distinctive: high device cost, a two-stage pathway in which the first stage generates the evidence required for the second, and an increasing share of cases subject to advance review by a payer or a federal contractor. Leaders should evaluate the program on the metrics that actually govern its economics.

Metrics That Matter

Metric	Why It Governs Program Economics
First-pass approval rate	The leading indicator of documentation architecture quality. Every point of improvement removes rework, shortens time to therapy, and, in WISeR states, protects exemption eligibility.
Trial-to-permanent conversion rate	A rate that is very low suggests patient selection problems; a rate approaching 100 percent invites scrutiny of trial rigor. Track it, understand it, and be able to explain it.
Days from candidacy to trial, and trial to permanent	The primary driver of patient attrition and of the authorization-expiration failure mode.
Denial rate by criterion	The only denial metric that tells you what to fix. Dollar-based denial reporting obscures the actionable pattern.
Peer-to-peer overturn rate	A high overturn rate on documentation-gap denials means the packet, not the clinical decision, is the problem.
Authorization expiration and lapse rate	Should be effectively zero. Any non-zero rate is a scheduling control failure.
Post-payment recovery exposure	Particularly relevant in Original Medicare jurisdictions where no advance authorization applies and NCD 160.7 compliance is enforced retrospectively.

Compliance and Governance

• The absence of a prior authorization requirement is not the absence of a coverage requirement. In Original Medicare jurisdictions outside the WISeR states and outside the hospital outpatient department program, NCD 160.7 compliance is enforced through post-payment review. Programs should document to the same standard regardless of whether advance review applies.
• Neurostimulator implantation has been the subject of federal oversight attention, including Office of Inspector General work informing the selection of services for the WISeR Model. Documentation discipline is a compliance posture, not only a revenue posture.
• Establish a pre-publication and pre-submission quality assurance process with defined roles: a certified coder verifying CPT®, HCPCS, and ICD-10-CM selection, and a clinical reviewer verifying device, FDA labeling, and clinical claims.
• Maintain an auditable record of which coverage document version was relied upon for each authorization. When criteria change mid-year, this record is the difference between a defensible decision and an indefensible one.

Artificial Intelligence Governance

The WISeR Model explicitly tests artificial intelligence and machine learning in Medicare medical review, with the safeguard that non-affirmation determinations must be reviewed by a human clinician with relevant clinical expertise before issuance. Provider organizations are simultaneously adopting automation for packet assembly and criteria matching. Both developments require governance.

• Automation should assemble and check documentation, not author clinical assertions. A generated medical necessity statement that asserts facts not in the record is a compliance exposure, not an efficiency gain.
• Maintain human accountability for every submitted assertion. The submitting organization owns the accuracy of the packet regardless of how it was produced.
• Review the licensing terms of any payer criteria used to train or operate automated tooling. At least one major utilization management vendor's published guidelines expressly prohibit use by external artificial intelligence entities without written permission. Obtain legal review before building automated tooling on payer criteria content.
• Where a payer applies automated review, the practical implication is that structured, explicit, well-labeled documentation performs better than narrative that requires inference. This favors exactly the documentation discipline recommended throughout this guide.
• Track determination patterns. A sudden change in denial rate or denial rationale may reflect a model or criteria change rather than a change in case mix, and warrants direct inquiry to the reviewing entity.

Back to guide navigation

25

GoHealthcare MSK Specialty Procedure Library™

GoHealthcare Prior Authorization Insight

This section contains operational knowledge that is not available in payer policies or clinical guidelines, drawn from supporting neuromodulation authorization across musculoskeletal specialty practices nationally.

The Five Structural Decisions That Determine a Program's Approval Rate

• 1. Where the conservative care ledger lives. Programs that maintain a standing, structured ledger from the first pain visit outperform programs that reconstruct history at the point of request by a wide margin. This is a chart-architecture decision, not an authorization decision.
• 2. Who owns the rulebook. A single named individual should own coverage-document currency for the practice and re-verify quarterly. Distributed ownership produces templates built on retired LCDs.
• 3. Whether pre-submission review is independent. Self-review does not work. The assembler and the clearer must be different people.
• 4. Whether the operative planning note captures approach rationale. A single required field for the paddle rationale is the highest-yield template change available in WISeR states.
• 5. Whether denials feed back into templates. Programs that close this loop monthly improve continuously; programs that track denials only financially do not improve at all.

What Reviewers Actually Look For, in Order

Reviewers work under time pressure against a criteria checklist. In practice they search the packet in a predictable sequence. Structuring the packet to match that sequence measurably shortens review and reduces requests for additional information.

1. Is there a specific covered diagnosis, coded specifically, corroborated by imaging or examination?
2. Is there an itemized conservative care record with dates and outcomes meeting the applicable duration?
3. Is there a psychological or behavioral health evaluation with an explicit suitability conclusion?
4. For permanent requests: is there a quantified trial outcome with a percentage and a functional measure on the same instruments used at baseline?
5. Are the requested codes, laterality, levels, and site of service internally consistent and consistent with the described procedure?
6. For paddle requests: is there a stated rationale that percutaneous placement is inappropriate?
7. Are the enumerated contraindications affirmatively addressed?

Internal Quality Assurance Recommendations

• Run a monthly audit of ten randomly selected submitted packets against the applicable checklist. Score by criterion. Report the criterion-level failure rate, not an aggregate quality score.
• Maintain a criteria-change log. Record every observed change in a governing document, the date observed, the source, and the template change made in response.
• Reconcile authorization numbers and UTNs against booked cases weekly, before claims drop.
• Audit trial documentation specifically and separately. It is the highest-value and most frequently deficient element in the entire pathway.
• Before publication or external use of any derived work referencing payer criteria, obtain coder sign-off on code accuracy and clinical reviewer sign-off on device and regulatory claims.

Back to guide navigation

26

GoHealthcare MSK Specialty Procedure Library™

GoHealthcare Case Study

The following case study is an original educational composite. It does not describe any actual patient, physician, practice, facility, or payer, and any resemblance to a specific organization or individual is unintended.

Clinical Scenario

A 68-year-old patient with Original Medicare presents to a multi-site pain management group in a WISeR model state. The patient has persistent bilateral lower extremity neuropathic pain four years after an L4-L5 decompression and instrumented fusion, with a baseline numeric rating scale score of 8 out of 10 and an Oswestry Disability Index of 58. Prior instrumentation is present at the intended lead level. Conservative management over three years includes gabapentin and duloxetine at therapeutic doses, two courses of physical therapy, three transforaminal epidural steroid injections with transient relief, and cognitive behavioral therapy. Repeat surgical evaluation concluded that no further decompression or revision fusion was indicated. The implanting physician plans a percutaneous trial followed by permanent implantation using an open paddle electrode approach, given the prior instrumentation and epidural scarring.

Documentation Challenges

• Conservative care spanned three years and two health systems. The medication trials predated the current electronic record and existed only as a summary phrase.
• The physical therapy records were held by an outside facility and had not been requested.
• The psychological evaluation on file was eighteen months old, described the assessment, and concluded only that the patient was "cleared for procedure."
• Baseline function had been recorded once using the Oswestry Disability Index, but subsequent visits recorded only a numeric pain score.
• The operative planning note described the paddle approach but contained no statement of why percutaneous permanent placement was inappropriate.

Prior Authorization Barriers

• The trial was planned for the group's ambulatory surgery center and the permanent implantation for the affiliated hospital outpatient department, creating a site-of-service change between stages.
• The permanent implantation was planned as CPT® 63655 in a WISeR state, placing it within the model's scope.
• The team initially assumed that because the trial required no authorization in the ASC, the hospital outpatient permanent implantation would proceed on the same basis.

Payer and Program Considerations

• Under Original Medicare, NCD 160.7 governs coverage. No restrictive local coverage document limited the diagnosis in this jurisdiction, so the coverage question turned entirely on documented intractability, screening, and trial response.
• CPT® 63655 is subject to WISeR prior authorization or pre-payment review in the model states, with a three-calendar-day standard determination timeframe and a 120-day validity period.
• Associated services — anesthesia, the device, the physician service, and the facility claim — would be denied if the primary service were non-affirmed or denied.

Operational Workflow Applied

1. The authorization lead performed a Stage 0 rulebook determination and identified that the planned permanent code and state placed the case in WISeR scope, and that the site-of-service change between stages required independent handling.
2. Outside physical therapy records and prior medication documentation were requested immediately and assembled into a structured conservative care ledger with dates, doses, and measured outcomes.
3. The patient was referred for an updated psychological evaluation using a template requiring an explicit candidacy conclusion. The evaluation identified moderate untreated depressive symptoms, concluded they were modifiable, and recommended a course of treatment. Treatment was completed and a brief re-evaluation confirmed suitability.
4. Baseline Oswestry Disability Index and numeric rating scale scores were re-established at the pre-trial visit, and the patient was issued a structured trial diary.
5. The trial was performed with baseline and post-trial measurement on the same instruments.
6. A required rationale field was added to the operative planning note, and the physician documented that prior instrumentation and epidural fibrosis at the target level precluded safe and durable percutaneous permanent lead placement, corroborated by the imaging finding.
7. The permanent request was assembled against the WISeR documentation expectations, addressing each of the five elements in sequence, and submitted with a physician-signed medical necessity statement.

Resolution Strategy and Outcome

The trial produced a documented 65 percent reduction in target lower extremity pain, a reduction in Oswestry Disability Index from 58 to 34, and a documented reduction in analgesic use, all captured contemporaneously in the trial diary and confirmed at the post-trial visit. The permanent request received a provisional affirmation within the standard determination timeframe. The expiration date was entered into the surgical scheduling record, the case was performed within the validity window, and the Unique Tracking Number was reconciled to the facility claim before submission. The associated anesthesia, device, physician, and facility claims adjudicated without suspension.

Lessons Learned

• The rulebook determination was the decisive step. Had the team proceeded on the assumption that no authorization was required, the case would have entered pre-payment review with a 45-day documentation clock and full episode exposure.
• The paddle rationale was the criterion most at risk. Four of the five WISeR documentation expectations were already satisfied by competent clinical practice. The fifth existed only in the physician's judgment until a template change captured it.
• The conditional psychological evaluation strengthened the case. Identifying a modifiable concern, remediating it, and documenting both was more persuasive than the prior two-line clearance note.
• Instrument consistency made the trial outcome usable. Re-establishing the Oswestry Disability Index before the trial converted an unquantifiable functional claim into a measured change.
• Site-of-service change is a control point, not a detail. The hard scheduling rule requiring authorization re-review on any site change is what surfaced the issue in time.

Back to guide navigation

27

GoHealthcare MSK Specialty Procedure Library™

GoHealthcare Best Practices

• Maintain a standing conservative care ledger opened at the first pain management visit.
• Assign single-owner accountability for coverage document currency, re-verified quarterly and on every unfamiliar denial rationale.
• Record the governing document identifier, version, and effective date in every authorization record.
• Require independent pre-submission review by someone other than the packet assembler.
• Use validated pain and function instruments, and use the same instrument at baseline and follow-up without exception.
• Issue a structured trial diary to every trial patient.
• Require an explicit candidacy conclusion in every psychological or behavioral health evaluation.
• Add a required approach-rationale field to the operative planning note for all open paddle requests.
• Treat any site-of-service change between trial and permanent implantation as a mandatory authorization re-review.
• Track authorization expiration dates in the surgical scheduling record as hard constraints.
• Treat the Unique Tracking Number as a required case field with a named owner and reconcile weekly.
• Prepare a one-page peer-to-peer brief for every scheduled peer-to-peer conversation.
• Report denials by criterion and close the loop into templates within thirty days.
• Obtain coder and clinical reviewer sign-off before publishing or externally distributing any derived guidance.
• Obtain legal review before building automated tooling on proprietary payer criteria content.

Back to guide navigation

28

GoHealthcare MSK Specialty Procedure Library™

Common Mistakes

• Assuming a single national rulebook. Neuromodulation is governed by different programs depending on code, state, and site of service.
• Assuming that no advance authorization means no coverage requirement. Post-payment review enforces NCD 160.7 regardless.
• Routing CPT® 63650 to WISeR. It is expressly excluded because it sits in the hospital outpatient department program.
• Assuming the trial authorization covers the permanent implantation after a site-of-service change.
• Submitting a psychological clearance note in place of an evaluation with a suitability conclusion.
• Recording trial success as an impression rather than a percentage on a named instrument.
• Changing measurement instruments between baseline and follow-up.
• Omitting the rationale for an open paddle approach.
• Building templates on a retired local coverage document.
• Reusing a generic medical necessity letter that never names the policy it addresses.
• Submitting a 400-page record dump in which the decisive document is unfindable.
• Requesting a repeat trial after a documented sub-threshold trial without extenuating circumstances documented contemporaneously.
• Submitting a request for an indication the applicable criteria set categorically excludes, without a deliberate exception or appeal strategy.
• Letting an approved authorization lapse during a scheduling delay.
• Omitting the Unique Tracking Number from the claim.
• Proceeding to surgery on a non-affirmed determination without a deliberate financial decision and, where appropriate, an Advance Beneficiary Notice.
• Requesting expedited review without a supportable basis, which under WISeR results in reclassification to the standard timeframe.
• Reporting field stimulation under a named-peripheral-nerve code rather than the unlisted code.
• Coding an integrated single-component system under the two-component code family, or the reverse.
• Reporting electronic analysis separately on the day of implantation.

Back to guide navigation

29

GoHealthcare MSK Specialty Procedure Library™

Pearls and Pitfalls

Pearl	Corresponding Pitfall
Determine the rulebook before assembling the packet.	Assembling an excellent packet against the wrong policy.
A conditional psychological evaluation with documented remediation is stronger than a bare clearance.	Suppressing an evaluation that identifies modifiable concerns.
The trial diary converts recollection into contemporaneous data.	Reconstructing trial outcome at the post-trial visit from memory.
A documented contraindication satisfies most criteria sets as fully as a documented trial of therapy.	Omitting contraindications and intolerances from the conservative care record.
The paddle rationale is a two-sentence entry that decides the case.	Leaving a technical surgical judgment undocumented because it is obvious to the surgeon.
Unlimited resubmission under WISeR makes mechanical denials cheap to fix.	Constructing a clinical appeal in response to a clerical failure.
Peer-to-peer is won in the one-page brief prepared beforehand.	Sending the physician into a peer-to-peer without the denial rationale in front of them.
Early affirmation-rate discipline protects WISeR exemption eligibility.	Submitting thin early packets and accumulating non-affirmations that foreclose exemption.
Naming the policy in the submission accelerates review.	Submitting a generic letter that forces the reviewer to map criteria themselves.
MR conditionality documented pre-implant prevents post-implant dissatisfaction and explant.	Treating MRI compatibility as a consent formality rather than a selection criterion.
Associated services follow the primary determination.	Modeling financial exposure on the facility fee alone.
Denial data is only actionable at the criterion level.	Reporting denials in dollars and concluding that payers are simply difficult.

Back to guide navigation

30

GoHealthcare MSK Specialty Procedure Library™

Frequently Asked Questions

Q: Is prior authorization required for spinal cord stimulation under Original Medicare?

It depends on the code, the state, and the site of service. CPT® 63650 requires prior authorization nationwide when performed in a hospital outpatient department, under the CMS Prior Authorization Program for Certain Hospital Outpatient Department Services. CPT® 63655 is subject to prior authorization or pre-payment review under the WISeR Model in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. Outside those circumstances, Original Medicare does not require advance authorization, but NCD 160.7 compliance is enforced through post-payment review.

Q: Does the WISeR Model apply to CPT® 63650?

No. WISeR expressly excludes codes already subject to prior authorization under existing CMS programs, and 63650 is in the hospital outpatient department program. The WISeR electrical nerve stimulator code is 63655.

Q: Does WISeR apply to Medicare Advantage patients?

No. WISeR applies to Original Medicare only. Medicare Advantage and Railroad Medicare beneficiaries are excluded. Medicare Advantage plans apply their own utilization management, subject to the requirement that fully established Medicare coverage criteria govern where they exist.

Q: If both the trial and the permanent implantation occur in the same hospital outpatient department, do I need two authorizations?

Under the hospital outpatient department program, no. A provider performing both stages using CPT® 63650 in the same hospital outpatient department submits a prior authorization request for the trial only, and places the resulting Unique Tracking Number on the claim for the permanent implantation.

Q: What if the trial is performed in the ASC and the permanent implantation in the hospital outpatient department?

A prior authorization request must be submitted for CPT® 63650 as part of the permanent implantation procedure in the hospital outpatient department. This is the most common avoidable failure in the program.

Q: What trial threshold do payers actually apply?

At least a 50 percent reduction in target pain is the dominant standard, and many payers accept at least a 50 percent reduction in analgesic medication as an alternative. The WISeR documentation expectation for permanent paddle implantation pairs 50 percent pain reduction with evidence of functional restoration. Document both pain and function.

Q: How long must the trial last?

Medicare does not specify a duration, requiring only demonstration of relief with a temporarily implanted electrode. Several commercial criteria sets define a short-term trial as exceeding 48 hours. Follow the applicable policy and document the placement and removal dates.

Q: Can we repeat a trial that failed?

Several criteria sets treat a repeat trial after a failed trial as not medically necessary, and several local coverage articles state that a repeat trial is not appropriate absent extenuating circumstances, with additional documentation permitted on appeal. Where extenuating circumstances exist, document them at the time of the failure.

Q: Is a psychological evaluation always required?

NCD 160.7 conditions coverage on multidisciplinary screening that includes psychological evaluation, and it is required in principle by most commercial criteria. The format varies from full psychometric testing to a behavioral health attestation, and at least one vendor removed its behavioral health statement requirement in a 2026 revision. Do not assume the requirement is waived for a given plan without verifying.

Q: How recent must the psychological evaluation be?

Policies vary and many are silent. As an operational standard, an evaluation older than twelve months at the time of the permanent request should be refreshed, particularly where the clinical picture or psychosocial situation has changed.

Q: Why was our dorsal root ganglion stimulation request denied when the patient clearly has CRPS?

Because at least one major utilization management vendor treats DRG stimulation as not medically necessary for all indications except replacement of an existing DRG system. This is a categorical coverage position, not a documentation deficiency, and a standard medical necessity appeal is unlikely to succeed. Pursue the medical exception pathway and external review, and verify whether the plan's own policy or the vendor's criteria govern.

Q: Is peripheral nerve stimulation covered?

Inconsistently. Medicare addresses peripheral nerve stimulation through LCD L37360 and associated Article A55531, and dedicated CPT® codes exist. At least one major commercial vendor classifies peripheral nerve stimulation and peripheral nerve field stimulation as experimental, investigational, or unproven for pain. Verify the specific criteria set before scheduling.

Q: How do we code peripheral nerve field stimulation?

With unlisted code 64999. There is no named target nerve, so the peripheral nerve codes do not apply. Expect manual review and submit a narrative description with the claim. Coverage is rare.

Q: Is spinal cord stimulation covered for painful diabetic neuropathy?

This is the sharpest divergence in the category. It is an FDA-approved indication supported by randomized evidence and is accessible under Medicare in jurisdictions applying NCD 160.7 without restrictive diagnosis edits. At least one commercial vendor added it under strict criteria; at least one other lists peripheral neuropathy among non-covered indications. Verify per patient, per plan.

Q: What is the difference between the two-component and integrated code families?

A two-component system has a separate pulse generator requiring pocket creation and a detachable connection to the electrode array, and is reported with separate array and generator codes. An integrated system combines the electrode array and neurostimulator in a single unit and is reported with the integrated codes, which include imaging guidance. The operative note must describe the architecture that supports the code reported.

Q: Do we report fluoroscopy separately?

No. Fluoroscopy is included in the descriptors of the lead removal and revision codes, and imaging guidance is included in several integrated-system code descriptors. Electronic analysis is likewise inherent to the implantation codes and is not separately reported on the day of implantation.

Q: How often can programming be billed?

Several local coverage articles state that electronic analysis services are generally not considered medically necessary more often than once every 30 days. Simple programming adjusts one to three parameters; complex programming adjusts more than three. A parameter adjusted multiple times in one session counts once.

Q: Do we need a new trial to replace a device at end of service?

Generally no. Several local coverage documents provide that where a stimulator has been working well and requires replacement for battery change, malfunction, or end of stimulator life, a new trial is not needed. Document prior therapeutic benefit, the nature of the failure, and warranty status where the applicable policy requires it.

Q: Can we replace a conventional system with a high-frequency system?

Several criteria sets treat replacement of a functioning conventional dorsal column stimulator with a high-frequency system as not medically necessary. Where a modality change is clinically indicated, document the specific clinical rationale rather than presenting it as a routine replacement.

Q: What happens if we proceed without prior authorization under WISeR?

The claim is suspended and routed to the model participant for pre-payment medical review. The provider has 45 calendar days to respond to the documentation request; failure to respond results in denial. A determination is issued to the MAC within three days of receipt of complete documentation.

Q: Can we appeal a WISeR non-affirmation?

A non-affirmation is not an initial determination and is not itself appealable. However, resubmission is unlimited and peer-to-peer review may be requested with a resubmission. If the service is rendered and the claim is denied, that denial is an initial determination carrying full Medicare appeal rights.

Q: How long is a WISeR affirmation valid?

One hundred twenty calendar days from the decision date. Services not delivered within the window require a new prior authorization request and a new Unique Tracking Number.

Q: How do we earn WISeR exemption status?

By submitting at least ten prior authorization requests across WISeR select items and services during an assessment period and achieving a minimum affirmation threshold. Notifications began in June 2026 and are issued quarterly. Exempt providers are reevaluated through a limited number of additional documentation requests annually and receive at least 60 days' notice before loss of status.

Q: Are anesthesia and device charges at risk if the primary service is denied?

Yes. Under WISeR, associated items and services — anesthesia, implanted devices, physician services, and facility services — are denied where the primary service is non-affirmed during prior authorization or denied during claims processing. Model the full episode exposure.

Q: Should we issue an Advance Beneficiary Notice after a non-affirmation?

Where a non-affirmation is issued because the service was determined not medically reasonable and necessary and the provider intends to proceed, an ABN should be issued in advance of performing the service and the claim submitted with the GA modifier. Follow standard ABN policy and confirm current guidance before implementing a standing practice.

Q: Does the same physician have to perform the trial and the permanent implantation?

Several policies express a preference that the physician performing the trial also perform the permanent implantation, and provide that where this is not possible the patient should be informed in writing and given the name of the referral surgeon. Document the written notification where the implanter differs.

Q: How should we handle workers' compensation neuromodulation requests?

Workers' compensation is governed by state treatment guidelines and statutory utilization review timelines that frequently differ from group health norms, including in the psychological evaluation requirement and in the permissible number of trials. Identify the applicable state guideline at Stage 0 and build the packet to it.

Q: What is the single highest-yield change we can make to improve approval rates?

Maintaining a standing, structured conservative care ledger from the first pain visit, with dates, doses, and measured outcomes. If a program can make only one change, it should be that one. In WISeR states, the second is adding a required approach-rationale field to the operative planning note.

Q: How often should we re-verify coverage documents?

Quarterly at minimum, and immediately whenever a denial cites a criterion the team does not recognize. Local coverage determinations are retired and revised, billing and coding articles change independently of the LCD, and commercial vendors publish annual review revisions with future effective dates.

Q: Can we build automated tooling on payer criteria to speed up authorization?

Proceed only with legal review. At least one major utilization management vendor's published guidelines expressly prohibit use by external artificial intelligence entities without written permission. Automation that assembles and checks documentation carries lower risk than automation that ingests and reproduces proprietary criteria content.

Back to guide navigation

31

GoHealthcare MSK Specialty Procedure Library™

Key Takeaways

• Neuromodulation is governed by three simultaneous federal regimes plus the commercial layer. Which applies depends on the code, the state, and the site of service — never on the therapy alone.
• NCD 160.7 is the architectural source of nearly every criterion in the category: late resort, failed or unsuitable alternatives, multidisciplinary and psychological screening, demonstrated trial relief, and adequate facilities.
• The local coverage landscape is genuinely non-uniform. Several MACs retired their SCS local coverage determinations and apply the national determination directly; others maintain active documents with lifetime trial limits, lead limits, and diagnosis edits. Verify your own jurisdiction quarterly.
• CPT® 63650 sits in the nationwide hospital outpatient department prior authorization program; CPT® 63655 sits in the WISeR Model in six states. They do not overlap, and confusing them produces denials.
• The WISeR Model introduced technology-enhanced review into Original Medicare on January 1, 2026, with three-day determinations, 120-day validity, unlimited resubmission, peer-to-peer on resubmission, and an exemption pathway for high-performing providers.
• Commercial divergence concentrates in four places: dorsal root ganglion stimulation, peripheral nerve stimulation, painful diabetic neuropathy, and advanced waveforms. These are coverage positions, not documentation problems, and require a different response.
• The trial is the hinge of the authorization. Quantify pain reduction, analgesic reduction, and functional improvement on the same named instruments used at baseline, and state explicitly that the applicable threshold was met.
• The psychological evaluation must reach an explicit suitability conclusion. A conditional clearance with documented remediation is stronger than a bare clearance note.
• For open paddle requests, the affirmative rationale that percutaneous placement is inappropriate is the criterion most often missing and the easiest to fix.
• Most denials are documentation architecture failures, not clinical disagreements. Report denials by criterion, close the loop into templates monthly, and the approval rate moves.
• Associated services follow the primary determination. Model the full episode, not the facility fee.
• Absence of a prior authorization requirement is not absence of a coverage requirement. Document to the same standard everywhere; post-payment review is the enforcement mechanism.

Back to guide navigation

32

GoHealthcare MSK Specialty Procedure Library™

Future Outlook

• Expansion of technology-enhanced review. The WISeR Model runs through 2031 and CMS may update the select items and services list during the performance period. Practices outside the six model states should build to WISeR documentation standards now rather than retrofit under deadline. Deep brain stimulation and percutaneous image-guided lumbar decompression are explicitly scheduled for reevaluation in a future performance year.
• Maturation of the exemption or gold-carding concept. Threshold-based exemption is a structural shift: it converts documentation quality from a per-case concern into a program-level asset with prospective value. Expect commercial payers to continue expanding analogous gold-carding programs.
• Continued divergence on emerging modalities. Closed-loop and evoked-compound-action-potential-controlled stimulation, restorative neurostimulation, and expanding peripheral nerve stimulation indications will continue to outpace criteria updates. The gap between FDA clearance and coverage adoption remains the defining commercial friction in this category.
• Pressure on the painful diabetic neuropathy divergence. With randomized evidence, FDA-approved indications, and Medicare accessibility in many jurisdictions, categorical commercial non-coverage of this indication is increasingly difficult to sustain and is a reasonable target for organized appeal and policy engagement.
• Structured data submission. As payers and federal contractors apply automated review, the advantage will shift further toward structured, discretely captured, machine-readable documentation and away from narrative requiring inference. Practices that invest in structured capture now will benefit disproportionately.
• Artificial intelligence governance on both sides. Payer-side automation is now explicitly part of Medicare demonstration policy, with human clinician review required before non-affirmation. Provider-side automation is expanding. Expect increasing attention to transparency, auditability, licensing of criteria content, and accountability for automated assertions.
• Outcome-linked coverage. The trajectory across musculoskeletal utilization management points toward requiring demonstrated, measured, durable functional benefit rather than procedural appropriateness alone. Programs that already capture validated outcomes longitudinally are positioned for that transition; programs that do not will face a difficult retrofit.

Back to guide navigation

36

Implementation Resources

Recommended Downloads

• Neuromodulation Conservative Care Ledger template (structured note or flowsheet)
• Trial Authorization Packet Checklist (Checklist A)
• Permanent Implantation Authorization Packet Checklist (Checklist B)
• Revision, Replacement, and Removal Checklist (Checklist C)
• Medical Necessity Statement structural template
• Patient Trial Diary (daily pain, analgesic use, sleep, and functional activity)
• Psychological Evaluation Referral Template with required candidacy conclusion
• Operative Planning Note addendum: Rationale for Open Paddle Approach
• Rulebook Determination Worksheet (code, state, site of service, program)
• Fifteen-Minute Peer-to-Peer Brief template
• Authorization Expiration Tracker for surgical scheduling
• Unique Tracking Number reconciliation log
• Quarterly Coverage Document Verification Log
• Denial-by-Criterion tracking workbook

Back to guide navigation

37

Implementation Resources

Visual Recommendations

Visual	Purpose and Placement
Rulebook decision tree	Branch on payer type, then code, then state, then site of service, terminating in one of four pathways: OPD program, WISeR, plan criteria, or no advance authorization. Place in Section 16.
Two-stage authorization process map	Swimlane diagram across physician, authorization team, scheduling, and facility, showing the trial and permanent transactions as separate flows with their own quality gates.
Coverage matrix heat map	Indications on one axis, payers and vendors on the other, with a three-state fill for covered, conditional, and not covered. The single most useful visual in the guide.
WISeR at a glance infographic	States, participants, codes in scope, timeframes, validity period, and exemption thresholds on one page.
Trial documentation before-and-after comparison	Side-by-side of insufficient versus defensible trial documentation, drawn from Section 18.
High-level neuroanatomy illustration	Epidural space, dorsal columns, dorsal root ganglion, and a representative named peripheral nerve, labeled for coverage vocabulary rather than surgical technique.
Code architecture diagram	Two-component versus integrated single-component systems mapped to their respective code families.
Documentation checklist one-pagers	Printable versions of Checklists A, B, and C formatted for point-of-care use.
Denial-by-criterion Pareto chart	Template for practices to populate with their own data, reinforcing criterion-level rather than dollar-level denial management.

Back to guide navigation

33

References and Related Reading

References

All references were verified as accessible in July 2026. Coverage documents, payer criteria, and code sets change frequently; confirm the current version before relying on any citation.

Centers for Medicare & Medicaid Services

1. Centers for Medicare & Medicaid Services. Medicare National Coverage Determinations Manual, Chapter 1, Part 2, Section 160.7, Electrical Nerve Stimulators. Website: https://www.cms.gov/medicare-coverage-database
2. Centers for Medicare & Medicaid Services. Medicare Coverage Database (search local coverage determinations and billing and coding articles by state). Website: https://www.cms.gov/medicare-coverage-database
3. Centers for Medicare & Medicaid Services. Prior Authorization for Certain Hospital Outpatient Department (OPD) Services. Website: https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/prior-authorization-pre-claim-review-initiatives/prior-authorization-certain-hospital-outpatient-department-opd-services
4. Centers for Medicare & Medicaid Services. Prior Authorization for Certain Hospital Outpatient Department Services: Frequently Asked Questions. Website: https://www.cms.gov/files/document/opd-frequently-asked-questions.pdf
5. Centers for Medicare & Medicaid Services, Center for Medicare and Medicaid Innovation. Wasteful and Inappropriate Service Reduction (WISeR) Model: Provider and Supplier Operational Guide, Version 6.0, last updated April 24, 2026. Website: https://www.cms.gov/files/document/wiser-provider-supplier-guide.pdf
6. Centers for Medicare & Medicaid Services. Wasteful and Inappropriate Service Reduction (WISeR) Model. Website: https://www.cms.gov/priorities/innovation
7. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Chapter 29, Appeals of Claims Decisions. Website: https://www.cms.gov
8. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Chapter 30, Financial Liability Protections. Website: https://www.cms.gov
9. Centers for Medicare & Medicaid Services. Medicare Benefit Policy Manual, Chapter 15, Covered Medical and Other Health Services. Website: https://www.cms.gov
10. Centers for Medicare & Medicaid Services. Medicare Learning Network (MLN) educational products. Website: https://www.cms.gov/training-education/medicare-learning-network

Medicare Administrative Contractor Local Coverage

1. Palmetto GBA. Local Coverage Determination L35136, Spinal Cord Stimulators for Chronic Pain. Website: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35136
2. Wisconsin Physicians Service Insurance Corporation. Local Coverage Determination L36204, Spinal Cord Stimulators for Chronic Pain. Website: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=36204
3. Noridian Healthcare Solutions. Local Coverage Determination L37632, Spinal Cord Stimulators for Chronic Pain. Website: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=37632
4. Centers for Medicare & Medicaid Services. Local Coverage Article A56876, Billing and Coding: Spinal Cord Stimulators for Chronic Pain. Website: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56876
5. Centers for Medicare & Medicaid Services. Local Coverage Article A55531, Billing and Coding: Peripheral Nerve Stimulation. Website: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=55531
6. Noridian Healthcare Solutions. Spinal Neurostimulator Implantation, prior authorization guidance. Website: https://med.noridianmedicare.com/web/jfb/specialties/surgery/spinal-neurostimulator-implantation

Utilization Management and Commercial Payer Criteria

1. eviCore by Evernorth. Comprehensive Musculoskeletal Management Guidelines, CMM-211, Spinal Cord and Dorsal Root Ganglion Stimulation. Website: https://www.evicore.com/provider/clinical-guidelines
2. eviCore by Evernorth. Comprehensive Musculoskeletal Management Guidelines, CMM-210, Implantable Intrathecal Drug Delivery Systems. Website: https://www.evicore.com/provider/clinical-guidelines
3. Carelon Medical Benefits Management. Clinical Appropriateness Guidelines: Interventional Pain Management, effective June 14, 2026. Website: https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2026-06-14/
4. Carelon Medical Benefits Management. Clinical Guidelines and Pathways (index). Website: https://guidelines.carelonmedicalbenefitsmanagement.com
5. UnitedHealthcare. Medicare Advantage Policy Guideline: Spinal Cord Stimulators for Chronic Pain. Website: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medadv-mp/spinal-cord-stimulators-chronic-pain.pdf
6. UnitedHealthcare. Medical Policy: Implanted Spinal Drug Delivery Systems. Website: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/implanted-spinal-drug-delivery-systems.pdf
7. Aetna. Clinical Policy Bulletin 0194: Spinal Cord Stimulation. Website: https://www.aetna.com/cpb/medical/data/100_199/0194.html
8. Aetna. Clinical Policy Bulletin 0011: Peripheral Electrical Nerve Stimulation for Pain. Website: https://www.aetna.com/cpb/medical/data/1_99/0011.html
9. Aetna. Clinical Policy Bulletin 0447: Complex Regional Pain Syndrome / Reflex Sympathetic Dystrophy: Treatments. Website: https://www.aetna.com/cpb/medical/data/400_499/0447.html
10. Cohere Health. Provider resources and clinical programs. Website: https://www.coherehealth.com
11. Evolent. Specialty utilization management resources. Website: https://www.evolent.com
12. TurningPoint Healthcare Solutions. Provider resources. Website: https://www.turningpoint-healthcare.com

Professional Societies and Coding Authorities

1. American Medical Association. CPT® Assistant: New and Revised Neurostimulator Codes. Website: https://www.ama-assn.org/system/files/cpt-assistant-neurostimulator-codes.pdf
2. American Medical Association. Current Procedural Terminology (CPT®). Website: https://www.ama-assn.org/practice-management/cpt
3. American Society of Interventional Pain Physicians (ASIPP). Website: https://www.asipp.org
4. American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine). Evidence-Based Consensus Guidelines on Patient Selection and Trial Stimulation for Spinal Cord Stimulation Therapy for Chronic Non-Cancer Pain. Website: https://asra.com/news-publications/asra-updates/blog-landing/guidelines
5. American Society of Pain and Neuroscience (ASPN). Website: https://aspnpain.com
6. International Neuromodulation Society (INS) and the Neurostimulation Appropriateness Consensus Committee (NACC). Website: https://www.neuromodulation.com
7. North American Neuromodulation Society (NANS). Website: https://www.neuromodulation.org
8. North American Spine Society (NASS). Website: https://www.spine.org
9. American Association of Neurological Surgeons (AANS). Website: https://www.aans.org
10. Congress of Neurological Surgeons (CNS). Website: https://www.cns.org
11. American Academy of Orthopaedic Surgeons (AAOS). Website: https://www.aaos.org
12. Spine Intervention Society (SIS). Website: https://www.spineintervention.org

Regulatory and Device Sources

1. U.S. Food and Drug Administration. Premarket Approval (PMA) database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm
2. U.S. Food and Drug Administration. 510(k) Premarket Notification database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
3. U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience (MAUDE) database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.cfm
4. Medtronic. Neuromodulation reimbursement and coding resources. Website: https://www.medtronic.com
5. Abbott Neuromodulation. Reimbursement resources. Website: https://www.neuromodulation.abbott
6. Boston Scientific. Neuromodulation reimbursement resources. Website: https://www.bostonscientific.com
7. Nevro Corporation. Website: https://www.nevro.com
8. Saluda Medical. Website: https://www.saludamedical.com
9. SPR Therapeutics. Website: https://www.sprtherapeutics.com
10. Nalu Medical. Website: https://www.nalumed.com
11. Curonix. Website: https://www.curonix.com
12. Flowonix Medical. Website: https://flowonix.com

Selected Peer-Reviewed Literature

1. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. New England Journal of Medicine. 2000;343(9):618-624.
2. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain. 2007;132(1-2):179-188.
3. North RB, Kidd D, Farrokhi F, Piantadosi S. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56(1):98-106.
4. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz high-frequency and traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: 24-month results from a multicenter, randomized, controlled pivotal trial. Neurosurgery. 2016;79(5):667-677.
5. Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months. Pain. 2017;158(4):669-681.
6. Petersen EA, Stauss TG, Scowcroft JA, et al. Durability of high-frequency 10-kHz spinal cord stimulation for patients with painful diabetic neuropathy refractory to conventional treatments: 12-month results from a randomized controlled trial. Diabetes Care. 2021;45(1):e3-e6.
7. Duarte RV, Nevitt S, Maden M, et al. Spinal cord stimulation for the management of painful diabetic neuropathy: a systematic review and meta-analysis of individual patient and aggregate data. Pain. 2021;162(11):2635-2643.
8. Mekhail N, Levy RM, Deer TR, et al. Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial. Lancet Neurology. 2020;19(2):123-134.
9. Hara S, Andresen H, Solheim O, et al. Effect of spinal cord burst stimulation vs placebo stimulation on disability in patients with chronic radicular pain after lumbar spine surgery: a randomized clinical trial. JAMA. 2022;328(15):1506-1514.
10. Traeger AC, Gilbert SE, Harris IA, Maher CG. Spinal cord stimulation for low back pain. Cochrane Database of Systematic Reviews. 2023;3:CD014789.
11. Chapman KB, Sayed D, Lamer T, et al. Best practices for dorsal root ganglion stimulation for chronic pain: guidelines from the American Society of Pain and Neuroscience. Journal of Pain Research. 2023;16:839-879.
12. Harden RN, McCabe CS, Goebel A, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 5th edition. Pain Medicine. 2022;23(Suppl 1):S1-S53.
13. Manchikanti L, Knezevic NN, Navani A, et al. Epidural interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) comprehensive evidence-based guidelines. Pain Physician. 2021;24(S1):S27-S208.

Back to guide navigation

34

References and Related Reading

Reading Recommendations

• Read first, in full: WISeR Provider and Supplier Operational Guide, current version, Sections 1 through 7 and Appendix A. This is the single most operationally dense document in the category and it is free.
• Read second: NCD 160.7 in the Medicare National Coverage Determinations Manual. It is short, and it is the source of nearly every downstream criterion.
• Read third: the local coverage determination and associated billing and coding article for your own MAC jurisdiction, or confirm that none is in effect.
• Read fourth: the CMS Prior Authorization Program for Certain Hospital Outpatient Department Services operational guide and frequently asked questions, if you operate in a hospital outpatient department.
• For clinical grounding: the ASRA Pain Medicine consensus guidelines on patient selection and trial stimulation, and the ASPN best practices for dorsal root ganglion stimulation.
• For the evidence base: the SENZA and Evoke randomized trials, the ACCURATE trial for dorsal root ganglion stimulation, and the Cochrane review of spinal cord stimulation for low back pain, read together for a balanced picture.
• For utilization management literacy: the current published criteria of whichever vendor reviews the majority of your commercial volume, read cover to cover once per year.

Back to guide navigation

39

Professional Notice

Educational Disclaimer

Educational Disclaimer. This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official guidance from the Centers for Medicare & Medicaid Services. Coverage policies, coding guidance, and reimbursement requirements change frequently and should always be verified with the applicable payer and current regulatory sources before a prior authorization request is submitted or a claim is filed.

This guide is not a procedural technique manual, a physician training resource, or a substitute for specialty society procedural guidance. It does not reproduce proprietary payer policy language; payer criteria are synthesized and summarized, and readers are directed to the original source documents cited in the References section. CPT® is a registered trademark of the American Medical Association. All third-party marks are the property of their respective owners.

GoHealthcare Practice Solutions is a national Musculoskeletal Specialty Management Services Organization supporting Pain Management, Orthopedic Surgery, Spine Surgery, Neurosurgery, Neuromodulation, and Ambulatory Surgery Centers with prior authorization, medical necessity, clinical documentation, revenue cycle management, utilization management, compliance, payer policy interpretation, artificial intelligence governance, and practice optimization. Website: https://www.gohealthcarellc.com

Developed by Pinky Maniri , Founder and Chief Executive Officer, GoHealthcare Practice Solutions. Part of the GoHealthcare MSK Specialty Procedure Library™, produced under the GoHealthcare Clinical Procedure Guide Standard v1.0.

Back to guide navigation

Verified Internal Resources

GoHealthcare Practice Solutions Resources

Neuromodulation Prior Authorization

GoHealthcare's specialty prior authorization resource for neuromodulation programs.

https://www.gohealthcarellc.com/neuromodulation.html

Prior Authorization Services

Specialty prior authorization operations, documentation review, and national service support.

https://www.gohealthcarellc.com/prior-authorization-services.html

Pain Management Prior Authorization

Specialty guidance for high-complexity interventional pain and implantable-device authorization.

https://www.gohealthcarellc.com/pain-management-prior-authorization.html

WISeR Prior Authorization Readiness

GoHealthcare analysis of the CMS WISeR Model and its operational implications for pain practices.

https://www.gohealthcarellc.com/blog/cms-wiser-pain-management-2026

GoHealthcare Blog

Operational, prior authorization, revenue cycle, compliance, and MSK specialty healthcare insights.

https://www.gohealthcarellc.com/blog

Strengthen Neuromodulation Authorization Operations

GoHealthcare Practice Solutions supports pain management, spine, neurosurgery, orthopedic, neuromodulation, and ambulatory surgery center programs across patient access, prior authorization, medical necessity, clinical documentation, coding alignment, denial prevention, appeals, and revenue-cycle operations.

Request a Practice Assessment Call 1 (800) 267-8752

Developed by

Pinky Maniri

MSc, BSc, CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF, Certified in Healthcare A.I. Governance

Founder and Chief Executive Officer of GoHealthcare Practice Solutions

Connect on LinkedIn Visit GoHealthcare

Professional and Educational Disclaimer

This content is provided by GoHealthcare Practice Solutions for general professional, operational, educational, and informational purposes only. It is not medical, legal, regulatory, compliance, coding, billing, reimbursement, financial, or payer-specific advice and does not establish a consultant-client, attorney-client, provider-patient, or other professional relationship.

Coverage requirements, utilization-management criteria, payer policies, medical-necessity standards, laws, regulations, coding rules, reimbursement methodologies, technology requirements, device labeling, and clinical guidance may change. Users must independently verify all information against current official sources, applicable contracts, federal and state requirements, payer-specific policies, CMS guidance, NCDs, LCDs, CPT®, HCPCS, ICD-10-CM, FDA labeling, and other authoritative materials before making operational, clinical, compliance, coding, billing, or financial decisions. No approval, payment, reimbursement, compliance outcome, clinical outcome, or business result is guaranteed.

This website is intended for healthcare organizations and professionals and does not provide patient care or patient-specific advice. Do not submit protected health information or other sensitive patient information through a public webpage. Consult qualified legal, compliance, coding, clinical, financial, cybersecurity, and reimbursement professionals regarding organization-specific circumstances.

Full Disclaimer Privacy Policy Terms of Use Contact Us